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MOLECULAR MECHANISMS OF THYROID GLAND DISEASES
M. Karbownik-Lewińska, J. Nauman, S. Sporny
W1:  
Thyronamines — Past, Present, and Future
J. Köhrle, C. Höfig
Institut für Experimentelle Endokrinologie & Endokrinologisches Forschungs-
-Centrum der Charité EnForCé, Charité Universitätsmedizin Berlin, CVK; 
Augustenburger Platz 1; D-13353 Berlin; Germany
Thyronamines	(TAM)	represent	a	new	class	of	thyroid	hormone	de-
rived	endogenous	signalling	compounds	with	remarkable	biological	
effects	on	body	temperature,	energy	metabolism,	cardiac	function	
and	neurotransmission.	TAM	may	be	formed	from	their	precursor	
iodothyronines	via	a	combination	of	deiodinase	and	decarboxylase	
reactions	in	target	tissues.	No	evidence	for	their	de novo	biosynthesis	
from	tyrosine	or	tyramine	and	iodination	of	the	iodine-free	thyro-
namine	 (T0AM)	has	been	presented	so	 far.	The	 three	deiodinase	
selenoenzymes	Dio1,	Dio2	and	Dio3	show	distinct	structure-activity	
relationships	in	deiodination	of	T4AM	and	its	derivatives	with	lower	
iodine	content.	The	putative	decarboxylase(s)	proposed	to	generate	
TAM	from	their	corresponding	iodothyronines	is	(are)	still	elusive.	
Human	aromatic	amino	acid	decarboxylase	apparently	does	not	
produce	TAM	from	 iodothyronines.	 3-Iodothyronamine	 (3T1AM)	
is	the	major	TAM	found	in	human	and	rodent	serum	and	to	some	
extent	T0AM	has	been	detected	too.	In	serum	3T1AM	is	avidly	bound	
to	apolipoprotein	B100,	which	might	explain	reported	differences	
in	3T1AM	serum	 levels	and	 its	 remarkably	 long	 serum	half-life.	
A	significant	amount	of	3T1AM	is	generated	in	peripheral	tissues	as	
demonstrated	in	T4	substituted	thyroidectomised	patients.	TAM	is	
metabolized	by	amine	oxidases	to	generate	thyroacetic	acids	(TAC).	
TAM	 interfere	with	cellular	uptake	and	efflux	of	 iodothyronines	
catalyzed	by	various	plasma	membrane	transporters.	Nevertheless,	
significant	uptake	and	cellular	accumulation	of	TAM	has	been	de-
monstrated.	Whether	3T1AM	exerts	its	biological	effects	via	G-protein	
coupled	cell	membrane	receptors	of	the	trace	amine	associated	recep-
tor	(TAAR)	family	as	well	as	by	interaction	with	cellular	organelles	
such	as	mitochondria	remains	to	be	studied.	Currently,	a	variety	of	
marked	effects	on	glucose	and	lipid	metabolism,	neurotransmitter	
transport	and	uptake,	cardiac	and	metabolic	parameters	have	been	
reported	both	at	pharmacological	 and	physiological	 concentra-
tion	levels	after	peripheral	or	central	administration	of	3T1AM	or	
T0AM	in	various	animal	models.	More	research	is	needed	to	better	
understand	the	physiological	and	pathophysiological	role	of	TAM	
formation	and	action.
W2:  
Molecular genetics of thyroid and polyglandular 
autoimmunity
G.J. Kahaly
Department of Medicine I, Gutenberg University Medical Center, Mainz, 
Germany
Polyglandular	 autoimmunity	 or	 failure	 encompasses	 various	
endocrine	disorders	of	autoimmune	origin	with	an	onset	in	chil-
dhood	(the	rare	juvenile	APS	type	I)	or	in	adulthood	(the	more	
frequent	APS	type	II	and	III).	Autoimmune	thyroid	diseases	(AITD)	
and	 type	 1	diabetes	 (T1D)	 are	 the	most	 common	autoimmune	
endocrine	disorders	within	the	complex	APS.	They	occur	frequ-
ently	together	in	the	same	individual.	The	disease	combination	
is	denominated	as	autoimmune	polyglandular	failure	syndrome	
type	3	variant	(APS3v).
Family	and	population	studies	showed	that	the	APS3v	syndrome	
has	a	strong	genetic	background.	Whole	genome	and	candidate	
gene	 approaches	 identified	 several	 gene	 variations	which	 are	
present	in	both	AITD	and	T1D.	Most	important	common	disease	
susceptibility	genes	are	HLA (chromosome	6),	CTLA-4 (chromosome	
2),	PTPN22	(chromosome	1), FOXP3 (X	chromosome)	and	the	IL-
-2Ralpha/CD25 gene	region	(chromosome	10),	all	of	them	contribu-
ting	to	the	susceptibility	to	APS3v.	With	respect	to	the	underlying	
pathogenetic	mechanisms,	these	genes	are	altogether	involved	in	
the	immune	regulation,	in	particular	in	the	immunological	synapse	
and	T-cell	 activation.	 In	addition	 to	 these	 common	genes,	 there	
are	further	candidate	genes	with	joint	risk	for	AITD	and	T1D,	in	
particular	the	ERBB3 gene	(chromosome	12)	and	CLEC16A gene	
(chromosome	16).	The	latter	one	might	be	involved	in	pathogen	re-
cognition.	AITD	and	T1D	share	common	susceptibility	gene	variants	
which	possibly	act	pleiotropically	as	risk	factors	for	the	development	
of	 autoimmunity	 in	APS3v.	The	 functional	 consequences	of	 the	
genetic	variants	as	well	 as	 their	 interactions	 should	be	explored	
in	greater	detail.	In	particular,	the	functional	consequences	of	the	
variants	of	FOXP3 predisposing	to	APS3v	need	to	be	elucidated.	
Finally,	further	large-scale	genomewide	associations	studies	of	SNP	
variations	capturing	many	thousand	individual	genetic	profiles	are	
warranted	in	order	to	identify	further	genes	which	are	linked	to	
the	etiology	ofAPS3v.
W3:  
Molecular mechanisms of thyroid hormone action  
in thyroid gland
A. Piekiełko-Witkowska
Department of Biochemistry and Molecular Biology, The Medical Center  
of Postgraduate Education
Thyroid	hormones,	 thyroxine	(T4)	and	triiodothyronine	(T3)	are	
synthesized	in	thyroid	gland	in	a	multistep	process	in	which	se-
veral	key	proteins	are	involved:	sodium-iodide	symporter	(NIS),	
pendrin	 (PDS),	 thyroperoxidase	 (TPO),	 and	 thyroglobulin	 (Tg).	
Thyroid	hormones	are	synthesized	under	strict	control	of	thyro-
tropin-stimulating	hormone	(TSH)	which	initiates	cAMP	signaling	
cascade	and	regulates	the	expression	of	NIS,	PDS,	TPO	and	Tg.	The	
main	source	of	T3	in	thyroid	gland	in	euthyroidism	is	hydrolysis	
of	thyroglobulin.	In	hyperthyroidism	the	activity	of	iodothyronine	
deiodinases	significantly	contributes	to	overall	 thyroidal	T3	pro-
duction,	reaching	up	to	50%	of	T3	produced	in	thyroid	gland	in	
severe	hyperthyroidism.
Thyroid	hormones	regulated	the	expression	of	multiple	genes	via	
two	mechanisms:	genomic	and	non-genomic	one.	In	the	genomic	
Redakcja	„Endokrynologii	Polskiej”	nie	ponosi	odpowiedzialności	za	treść	streszczeń.
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Table I. Genetic abnormalities depending on dysgenesis type 
♀ A ♀ A ♂ A ♀ E ♀ E ♂ E
PAX8 + +
TSHR + +
FOXE1 +
TPO + +
(A – thyroid agenesis, E – sublingual ectopic thyroid gland) and gender (♀ female, ♂ male)
mechanism	thyroid	hormones	bind	specific	thyroid	hormone	re-
ceptors	(TRs)	which	act	as	a	ligand-dependent	transcription	factors.
TRs	bind	to	specific	TRE	sequences	in	promoters	of	T3-regulated	
genes	and	modify	their	transcription.	In	the	non-genomic	mecha-
nism,	apart	from	TRs,	other	receptors	localized	in	plasma	membrane	
and	cytoplasm	are	involved.	They	induce	signaling	cascades	which	
result	in	broad	cellular	effects	including	changes	in	expression	of	
target	genes,	the	activity	of	membrane	channels,	and	changes	in	
elements	of	cytoskeleton.
Disturbances	in	TRs	were	discovered	in	pathologies	of	thyroid	
gland,	including	thyroid	neoplasia.	In	the	latter,	TRs’	mutations	
and	disturbances	of	expression	were	identified.	Mouse	models	
of	thyroid	cancer	suggest	that	thyroid	hormone	receptors	may	
function	 as	 tumor	 suppressor	 factors	 and	mutations	 in	 TRs	
may	 initiate	mechanisms	 leading	 to	 proliferation	 activation,	
apoptosis	 inhibition,	 and	 increased	 cell	motility	 resulting	 in	
metastasis.	The	identification	of	TRs-dependent	disturbances	of	
signaling	cascades	offers	therapeutic	opportunities	for	thyroid	
cancer	patients.
W4:  
Detection of genetic abnormalities in children with 
congenital hypothyroidism using MLPA analysis
M. Kumorowicz-Czoch1, A. Madetko-Talowska2, D. Tylek-
-Lemańska3, J.J. Pietrzyk2, J. Starzyk1
1Department of Pediatric and Adolescent Endocrinology, Chair of Pediatrics, 
Polish–American Institute of Pediatrics, Jagiellonian University Medical College, 
Cracow 
2Division of Medical Genetics, Chair of Pediatrics, Polish–American Institute  
of Pediatrics, Jagiellonian University Medical College, Cracow 
3Division of Mass Screening and Metabolic Diseases, University Children’s 
Hospital of Cracow
Introduction: Thyroid	dysgenesis	 (TD),	usually	 sporadic,	 is	 the	
most	common	cause	of	congenital	hypothyroidism	(CH).	Among	
genetic	 factors	 that	may	 contribute	 to	TD	etiopathogenesis,	 the	
highest	importance	is	ascribed	to	mutations	of	transcription	factors	
and	TSH	receptorencoding	genes.
Objective: Assessment	of	 incidence	of	 changes	 involving	genes	
encoding	PAX8,	FOXE1,	NKX2-1,	TSHR	detected	by	multiplex	liga-
tion-dependent	probe	amplification	(MLPA)	in	CH	and	TD	children.
Material and methods: Investigations	 included	46	 children	 se-
lected	 in	mass	screening	 tests	between	1995	and	2009,	 in	whom	
CH	 resulted	 from:	 ectopy	 (n	=	17),	 agenesis	 (n	=	22),	 thyroid	
hypoplasia	(n	=	7).
DNA	was	 isolated	 from	peripheral	blood	 samples	using	Master	
Pure	DNA	Purification	Kit	(Epicentre	Biotechnologies).	50–100	ng	
of	genomic	DNA	was	employed	in	MPLA	analysis	using	a	SALSA	
MLPA	kit	P319-A1	THYROID	 (MRC-Holland).	Genetic	 changes	
were	 analyzed	within	 selected	 fragments	of	 the	PAX8,	 FOXE1,	
NKX2-1,	TSHR	and	TPO	genes.	Testing	followed	a	standardized	
procedure	provided	by	the	manufacturer.	Stages	of	MLPA	analysis	
included:	DNA	denaturation,	MLPA	probe	hybridization,	ligation,	
PCR	reaction,	separation	of	reaction	products	by	capillary	electro-
phoresis	and	data	analysis.
Results: Four	types	of	heterozygous	deletions	in	probe	hybri-
dization	regions	were	identified	for	the	following	genes:	PAX8	
in	exon	7,	TSHR	 in	exon	2,	FOXE1	 in	exon	1and	TPO	 in	exon	
16.	Genetic	abnormalities	of	selected	gene	fragments	were	identified	
in	6/46	subjects	(Table	I).
Conclusions: MLPA	screening	 showed	genetic	 abnormalities	 in	
13%	of	CH	and	TD	children,	manifested	as	deletion	at	probe	hybri-
dization	site.	Precise	determination	of	the	character	of	such	abnor-
malities	and	genotype-phenotype	correlation	requires	extending	
the	study	of	selected	regions	to	include	other	molecular	methods	
(Sanger	sequencing).
W5:  
First Announcement of Glucagonlike Peptide- 
-1Receptor Imaging Positive Results in Patients  
with Medullary Thyroid Carcinoma (MTC)
A. Sowa-Staszczak1, D. Pach1, A. Jabrocka-Hybel1,  
A. Gilis-Januszewska1, E. Przybylik-Mazurek1,  
A. Stefańska1, M. Tomaszuk1, R. Mikołajczak2, B. Janota2,  
A. Hubalewska-Dydejczyk1
1Department of Endocrinology, Jagiellonian University School of Medicine, 
Kraków, Poland 
2Institute of Atomic Energy, Radioisotope Centre POLATOM, Otwock-Świerk, 
Poland
Introduction: MTC	accounts	 for	5–10%	of	all	 thyroid	cancers.	
In	some	MTC	patients	with	postoperative	calcitonin	elevation,	
basal	or	 in	pentagastrin	 test,	 and	negative	 imaging	 technique	
results	it	is	necessary	to	search	for	new	targets	for	radioisotope	
diagnostic.	Overexpression	of	GLP-1	receptors	have	been	shown	
on	different	types	of	neoplastic	cells,	among	others	on	parafol-
licular	thyroid	C-cells.	The	aim	of	this	study	was	to	present	the	
preliminary	 experiences	with	 the	use	of	 99mTc-labeled	GLP-1	
analogue	in	MTC	imaging.
Material and method: 99mTc-GLP-1	 receptor	 scintigraphy	
with	 [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4	was	
performed	in	3	patients.	The	first	case:	70yo	man,	with	disse-
mination	of	MTC	(2008),	treated	with	PRRT,	local	recurrence	of	
MTC	(2011).	The	second	case:	66yo	man,	metastatic	lesions	of	
MTC	in	liver	and	lymph	nodes	(2009),	treated	with	PRRT,	since	
then	stabilisation	of	the	disease.	The	third	case:	22yo	man,	with	
genetically	 confirmed	MEN2a	 syndrome,	 suspicion	 of	 local	
recurrence	after	abnormal	pentagastrin	test	(2009),	thyroid	US	
revealed	 hypogenic	 lesion	with	 subsequent	 negative	 biopsy	
result.	 The	 lyophilized	 kit	 prepared	 by	 IAE	 POLATOM	was	
used	 for	 preparing	 the	 tracer.	WB	 scans	were	 performed	 at	
6	time	points	and	SPECT	at	3	points.	The	hybrid	device	SPECT/	
/CT	was	used	to	perform	examinations.
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Results: In	 the	 first	 patient,	 recurrence	 of	 the	 disease	was	
assumed	after	GLP-1	scintigraphy.	In	the	second	patient,	a	pa-
thological	tracer	accumulation	in	the	liver	was	found.	For	both	
patients	the	similar	images	to	GLP-1	scintigraphy	were	obtained	
in	SRS	scintigraphy.	In	the	third	patient,	the	GLP-1	scintigraphy	
showed	the	tracer	uptake	in	the	same	place	as	99mTc	and	131I	
scans.	The	patient	was	qualified	to	neck	surgery.	In	all	patients	
no	side	effects	after	the	labeled	GLP-1	analogue	injection	were	
observed.
Conclusion: [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4	
seems	 to	be	a	promising	new	tracer	 for	clinical	practice	 in	MTC	
patients,	especially	when	standard	imaging	techniques	fail.
AUTOIMMUNE THYROID DISEASES
E. Bar-Andziak, R. Junik, W. Zgliczyński
W6:  
Oxidative stress and the thyroid gland
M. Karbownik-Lewińska
Department of Oncological Endocrinology; Chair of Endocrinology and Metabolic 
Diseases, Medical University of Lodz, Poland 
Polish Mother’s Memorial Hospital — Research Institute, Lodz, Poland
Key words: thyroid;	 thyroid	hormone	synthesis;	 free	radicals;	hy-
drogen	peroxide;	iron;	oxidative	damage;	antioxidant;	thyroid	cancer.
Reactive	oxygen	species	(ROS)	and	free	radicals	are	formed	in	living	
organisms	—	in	certain	amounts	—	under	physiological	conditions.	
An	overproduction	of	ROS	and	free	radicals	results	in	enhanced	
oxidative	stress	and	can	 lead	to	several	diseases.	The	most	basic	
reaction	of	oxidative	stress	is	Fenton	reaction:	Fe2+	+	H2O2	Æ	Fe
3+	
+	•OH	+	OH–.	Hydroxyl	radical	(•OH),	produced	in	this	reaction,	
is	the	most	toxic	free	radical.
Whereas	oxidative	reactions	occur	in	practically	all	tissues	and	organs,	
the	thyroid	gland	constitutes	such	an	organ,	in	which	ROS	(and	iron	as	
well)	are	indispensable	for	hormone	synthesis.	Mechanisms	of	ROS	ge-
neration	in	the	thyroid	gland	are	extensively	examined,	with	NADPH	
oxidases	possessing	the	primary	role	in	intracellular	H2O2	formation.	
Hydrogen	peroxide	is	indispensable	for	thyroid	hormone	synthesis,	
serving	as	a	limiting	co-factor	for	thyroid	peroxidase	(TPO)	at	all	steps	
of	 this	process.	Although	not	measured	up	to	now,	 iron	and	H2O2	
must	be	at	very	high	concentrations	in	the	thyroid	gland,	potentially	
creating	conditions	for	huge	oxidative	stress.	It	is	assumed,	therefore,	
that	the	increased	iron	supply	or	the	increased	H2O2		production	in	
the	thyroid,	resulting	from	redox	imbalance,	may	lead	to	enhanced	
oxidative	damage	and	consequently	to	initiation	of	different	disorders,	
cancer	included.	It	is	hypothesized	that	oxidative	stress	possesses	the	
primary	role	in	thyroid	cancer	initiation.
W7:  
Autoimmune disorders during pregnancy
A. Syrenicz
Department of Endocrinology, Metabolic and Internal Diseases Pomeranian 
Medical University in Szczecin
During	pregnancy	plenty	of	metabolic,	hormonal	and	immunologic	
changes	 take	place,	 that	have	significant	 influence	on	occurrence	
and	course	of	autoimmune	thyroid	dysfunctions	and	also	of	other	
autoimmune	disorders,	 such	as	Addison’s	disease,	 type	1	diabetes	
mellitus,	systemic	lupus	erythematosus	or	rheumatoid	arthritis.	During	
pregnancy	the	physiologic	immunosuppression	develops,	that	con-
cerns	either	the	cellular	response	with	following	decrease	of	helpers	
lymphocytes	to	suppressor	lymphocytes	ratio,	or	the	humoral,	that	is	
associated	with	a	decrease	of	most	antibodies	concentration,	including	
antithyroid	antibodies.	Induction	of	tolerance	in	the	placenta-decidual	
space	allows	the	pregnancy	to	develop	although	the	fetus	contains	the	
unfamiliar	for	maternal	organism	antigens,	which	derive	from	father.
Mechanisms	of	this	phenomenon	are	complicated.	Trophoblast	syn-
citium	cells	that	contain	big	quantities	of	indoleamine	2,3-dioxygen-
ase	enzyme	that	is	responsible	for	tryptophan	degeneration,	which	
lack	prevents	T-lymphocyte	proliferation	seem	to	be	most	significant	
in	immunologic	tolerance	induction.	The	syncytiotrophoblast	cells	
demonstrate	 the	unique	model	of	 tissue	 compatibility	 antigens	
presentation:	lack	of	classical	MHC-	HLA-A,	HLA-B,	HLA-DP,	HLA-
DQ	and	HLA-DR	and	presence	of	classical	HLAC	and	non-classical	
HLA-E	and	HLA-G	antigens	 expression,	 that	prevents	 the	NK	
(Natural	Killers)	cells	activation	and	CD8	cytotoxicity.	Moreover,	the	
syncytiotrophoblast	cells	express	the	Fas	ligand	with	the	following	
Fas	binding	on	activated	lymphocytes,	 that	 leads	to	 lymphocyte	
death	and	binding	with	Fas	of	the	complement	system,	that	leads	
to	its	activation	inhibition.	The	decidua	is	also	of	great	importance	
in	placenta-decidual	space	tolerance.	It’s	actually	known,	that	de-
cidua	is	infiltrated	with	uterine	NK	cells,	that	are	less	cytotoxic	and	
produce	big	amounts	of	immunoregulatory	cytokins.	The	decidua	
is	also	infiltrated	by	the	T-regulatory	cells,	that	are	significant	in	the	
embryo	implantation	process.	The	T-regulatory	cells	have	ability	to	
inhibit	the	other	T	cells	proliferation	and	activation	as	well	by	the	
direct	contact	as	by	immunosuppressive	Il-10	and	TGFβ	cytokins	
secretion.	Reassuming,	during	pregnancy	a	systemic	immunosup-
pression	does	not	develop,	 but	 the	 state	 of	 selective,	 transient	
tolerance	is	formed.	In	the	postpartum	period	the	phenomenon	of	
increased	immunologic	tolerance	disappears	and	even	a	so	called	
“rebound	phenomenon”	can	develop,	that	causes	the	present	before	
diseases	exacerbation	or	new	autoimmune	diseases	manifestation.
Out	of	autoimmune	thyroid	diseases	during	pregnancy	Graves-
Basedow’s	and	Hashimoto’s	diseases	should	be	remembered	about.	
Hyperthyroidism	caused	by	Graves-Basedow’s	disease	in	the	first	
pregnancy	 trimester	 can	 temporarily	 exacerbate,	 then	a	disease	
remission	begins	and	the	symptoms	of	hyperthyroidism	decrease,	
that	is	significant	in	therapeutic	decisions	taking.	Hypothyroidism	
caused	by	Hashimoto’s	disease,	despite	that	the	amount	of	anti-
thyroid	antibodies	during	pregnancy	decreases,	demands	usually	
about	50%	increase	of	substitutive	thyroxin	dose,	that	is	necessary	
for	the	proper	foetoplacental	unit	functioning.
W8:  
Interleukin 1 beta (IL-1beta) gene polymorphisms 
(SNP-511 and SNP+3953) in Hashimoto’s thyroiditis 
among the Polish population
K. Łącka1, A. Paradowska-Gorycka2, L. Kramer3,  
W.A. Herman4, A. Maciejewski5, J.K. Łącki6
1Department of Endocrinology, Metabolism and Internal Medicine, University  
of Medical Science, Poznan, Poland 
2Department of Biochemistry, Institute of Rheumatology, Warsaw, Poland 
3Department of Computer Science, University of Medical Sciences, Poznan, 
Poland 
4Outpatient’s Unit of Endocrine Diseases, Wschowa, Poland 
5Student’s Scientific Society, University of Medical Sciences, Poznan, Poland 
6Department of Public Health, University of Zielona Gora, Poland and Depart-
ment of Connective Tissue Diseases, Institute of Rheumatology, Warsaw, Poland
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Objective: The	role	of	cytokines	in	the	pathogenesis	of	Hashimoto’s	
thyroiditis	(HT)	is	well	confirmed,	but	association	of	certain	cytoki-
ne	genes	polymorphisms	with	susceptibility	and/or	course	of	this	
disease	needs	further	investigations.	Il-1	beta	which	is	produced	in	
the	HT	thyroid	may	induce	FAS	expression	in	normal	thyrocytes	
resulting	in	massive	thyrocyte	apoptosis	and	destruction.	Previous	
studies	did	not	reveal	any	association	between	selected	SNPs	of	
IL-1beta	gene	and	susceptibility	to	HT	among	the	Chinese	and	UK	
Caucasian	population.
Aim: This	study	presents	the	association	between	the	interleukin	1	
beta	(IL-1	beta)	gene	polymorphisms	at	-511	in	the	promoter	region	
(SNP-511)	and	+3953	in	exon	5	(SNP+3953)	and	susceptibility	to	
the	development	of	Hashimoto’s	 thyroiditis	 among	Caucasian-
-Polish	population.
Patients and methods: The	 studied	 group	 comprised	 of	 115	
unrelated	 patients	 with	 HT	 (112	 women	 and	 3	men	with	
a	mean	age	of	53	years).	All	patients	were	euthyroid	on	thyroid	
replacement	therapy,	and	all	patients	had	extremely	high	serum	
anti-TPO	levels	and	in	53	patients	anti-Tg	levels	were	also	incre-
ased.	The	control	group	consisted	of	103	healthy	blood	donors	
without	 raised	 anti-TPO	 antibodies,	 in	whom	a	personal	 and	
a	family	history	of	thyroid	and	autoimmune	as	well	as	inflam-
matory	diseases	was	excluded.	No	goiter	or	thyroid	dysfunction	
was	 found.	Two	polymorphisms	of	 the	 IL-1	beta	 (C-511T	and	
C+3953T)	were	studied	by	PCRRFLP	analysis.	To	confirm	the	
accuracy	of	the	method	employed,	randomly	selected	patients	
were	analyzed	by	direct	sequencing.
Results: Both	control	allele	frequencies	were	in	Hardy-Weinberg	
equillibrium.	The	 significant	 statistical	differences	between	 the	
frequency	of	C	allele	and	T	allele	for	both	SNPs	in	the	studied	gro-
up	and	in	the	controls	were	found	(p	=	0.008;	using	the	chisquare	
test).	The	frequencies	of	the	genotype	of	C-511C	compared	to	C-
-511T	and	T-511T	as	well	as	C+3953C	compared	to	C+3953T	and	
T+3953T	were	statistically	significant	(p	=	0.0190	and	p	=	0.0129;	
using	Fisher’s	exact	probability	test).
Conclusions: An	association	between	the	SNP	of	the	IL-1	beta	and	
susceptibility	to	Hashimoto’s	thyroiditis	among	the	studied	group	
of	Caucasian-Polish	population	was	found.
W9:  
The mechanism of cytotoxic reaction of lymphocytes 
and plasma cells against thyrocytes in Hashimoto’s 
thyroiditis
I. Beń-Skowronek1, L. Szewczyk1, R. Ciechanek2, E. Korobowicz3
1Department of Paediatric Endocrinology and Neurology Medical University  
in Lublin, Poland 
2Division of Surgery of Voivodship Hospital Lublin, Poland 
3Department of Pathomorophology, Medical University, Lublin, Poland
Background: The	aim	of	the	study	was	to	analyze	of	the	cytotoxic	
mechanism	of	action	the	cell	T	and	B	subsets	in	the	thyroid	tissue	
in	patients	with	Hashimoto’s	thyroiditis.
Methods: We	have	studied	paraffin	thyroid	specimens	obtained	
from	children	with	Hashimoto’s	thyroiditis,	and	children	without	
an	autoimmune	 thyroid	disease.	The	mononuclear	T-cells	were	
detected	by	CD3+,	CD4+,	CD8+	antibodies,	and	 the	B-cells	by	
CD79	 alpha+	antibodies	 (plasma	 cells)	 (DakoCytomation	Den-
mark),	and	they	were	counted	with	Sony	Colour	Camera	Exwave	
HAD	MultiScan5	system.	The	specimens	from	each	patient	were	
routinely	estimated	and	investigated	under	the	electron	microscope.
Results: In	Hashimoto’s	thyroiditis	we	observed	a	statistically	signifi-
cant	increase	in	T	suppressor/cytotoxic	cells	CD8+	(20.54	±	0.68%)	and	
plasmocytes	(31.65	±	9.11%)	in	the	case	of	low	number	of	T	helper	cells	
CD4+	(0.93	±	9.90)	in	the	thyroid	gland	in	comparison	with	children	
without	AITD.	The	ultastructural	investigations	showed	the	connec-
tions	of	cytotoxic	synapse	character	between	T-cells,	plasmocytes,	and	
thyrocytes	leading	to	apoptosis	of	thyrocytes.	The	tyrocytes	were	dam-
aged	in	course	of	cytotoxic	reactions.	The	second	mechanism	leading	
to	the	apoptosis	—	the	production	of	collagen	fibres	by	fibroblasts	and	
considerable	thickening	of	basal	membranes	of	the	thyroid	follicles.
Conclusions: In	Hashimoto’s	 thyroiditis,	autoantigen	presentation	
in	the	case	of	low	number	of	CD4+	Thelper	cells	and	increase	in	the	
number	of	CD8+	cells	and	plasmocytes,	leads	to	cytotoxic	reaction	
against	thyrocytes.	The	direct	contact	of	T-cells	and	plasma	cells	leads	to	
apoptosis	of	the	thyrocytes.	The	fibroblasts	are	involved	in	this	process.
THYROID CANCER
B. Jarząb, A. Lewiński, J. Brzeziński
W10:  
Identification and protection of important anatomi-
cal structures of the neck during thyroidectomy
J. Brzeziński, M. Dedecjus
Department of General, Oncological, and Endocrine Surgery, Polish Mother’s 
Memorial Hospital — Research Institute, Medical University of Lodz
The	superior	and	inferior	parathyroid	glands	should	be	identified	
and	preserved	before	resection	of	the	thyroid	gland.	The	superior	
parathyroid	gland	is	normally	present	approximately	1	cm	superior	
to	the	junction	of	the	recurrent	 laryngeal	nerve	and	the	inferior	
thyroid	artery.	The	inferior	parathyroids	are	typically	found	within	
1	cm	of	the	lower	pole.	Over	80%	of	superior	parathyroids	supply	
and	almost	 90%	of	 inferior	parathyroid	 supply	 is	 coming	 from	
inferior	thyroid	arteries.	Recurrent	laryngeal	nerve	on	both	sides	
should	be	identified	before	dissection	of	the	thyroid.
Intraoperative	neural	monitoring	is	very	helpful	especially	in	ca-
ses	in	which	the	visual	information	is	problematic.	Routine	visual	
identification	of	the	recurrent	laryngeal	nerve	reduces	the	incidence	
of	injury.	After	identification	and	prevention	of	important	anato-
mical	structures	of	the	neck	total	thyroidectomy	is	safety	done	by	
the	surgeons.
W11:  
Fine-needle aspiration biopsy (FNAB) of the thyroid 
gland — from pure morphology and morphometry  
to molecular diagnostics
A. Lewiński
Department of Endocrinology and Metabolic Diseases, Medical University, Lodz; 
Polish Mother’s Memorial Hospital — Research Institute, Lodz, Poland
The	main	goal	 of	diagnostics	 of	 thyroid	 lesions	 comprises	 the	
differentiation	between	benign	and	malignant	ones,	i.e.,	determi-
nation	of	nature	of	the	punctured	lesions,	and	—	in	consequence	
—	selection	of	a	group	of	patients	in	whom	surgical	treatment	in	
necessary.	During	this	diagnostic	procedure,	it	becomes	possible	to	
aspirate	fluid	from	cystic	lesions	in	the	gland.	The	ultrasonographic	
(US)-guidance	of	fine-needle	aspiration	biopsy	(FNAB)	is	absolutely	
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required	and	the	main	goal	of	US	is	a	selection	of	the	optimal	area	
for	FNAB,	by	monitoring	the	location	of	the	tip	of	biopsy	needle.
It	should	be	emphasized	that	there	is	a	new	approach	to	the	criteria	
of	typing	dominant	nodules,	selected	for	puncture	during	FNAB.	
Namely,	the	most	important	is	the	pattern	of	blood	flow	in	the	lesion	
and	US	features	of	nodule/focus	 (associated	with	malignancy	or	
suggesting	rather	a	benign	lesion),	and	not	the	diameter	of	nodule	
or	its	consistency,	evaluated	during	palpation.
The	American	and	European	Thyroid	Associations	(including	the	
Polish	Thyroid	Association),	as	well	as	the	Polish	Group	for	Endocri-
ne	Tumors,	recommend	to	perform	FNAB	of	foci	with	a	diameter	of	
10	mm	and	larger,	and	also	with	a	diameter	less	than	10	mm	in	pa-
tients	with	significant	clinical	risk	factors	for	the	presence	of	thyroid	
cancer,	including	patients	with	a	history	of	family	incidence	of	the	
disease	in	question,	also	in	patients	who	were	previously	exposed	to	
irradiation,	and	—	as	already	mentioned	—	in	all	the	patients	with	
suspicious	features	in	US	image.	There	is	controversy	regarding	the	
usefulness	of	individual	parameters	of	ultrasound	image	(shape,	
echogenicity,	 irregular	margins,	 the	presence	of	calcifications,	or	
pattern	of	the	blood	flow)	in	selecting	foci	for	diagnostic	puncture.	
It	 should	be	noted	 that	FNAB	 is	also	helpful	 in	establishing	 the	
diagnosis	in	cases	of	thyroiditis.
In	order	to	increase	the	diagnostic	efficacy	of	the	thyroid	cytological	
examination,	various	methods	 improving	 the	 evaluation	of	 the	
obtained	material	have	been	employed.	Some	of	those	methods,	in-
cluding	computerized	image	analysis,	add	quantitative	assessment	
to	routine	qualitative	evaluation	performed	by	cytopathologists.	
Some	other	methods	 employ	 additional	 immunocytological	 or	
other	 specific	 staining.	These	methods	 allow	determination	of	
detailed	histogenesis	of	 aspirated	 cells,	 and,	 in	 some	 cases,	 the	
distinguishing	between	malignant	and	benign	lesions.	Molecular	
biology	techniques	are	also	used	for	that	purpose.
Nowadays,	the	development	of	novel	techniques	of	RNA	storing	
and	 isolation	enables	elimination	of	extra	punctures	and	proves	
diagnostic	utility	of	a	small	number	of	cells	remaining	in	the	biopsy	
needle	after	routine	cytological	smear.	New	methods	of	molecular	
biology	are	of	such	sensitivity	that	they	allow	obtaining	an	unam-
biguous	diagnosis	even	when	aspirates	are	assessed	as	inadequate	
or	undetermined	for	cytological	analysis.
W12:  
Polish guideline on treatment of thyroid cancer
B. Jarząb, D. Handkiewicz-Junak
Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, 
Gliwice Branch
Thyroid	carcinoma	is	rare	among	human	malignancies	(<	1%),	but	
is	the	most	frequent	endocrine	cancer,	accounting	for	about	5%	of	
thyroid	nodules.	More	than	75%	of	malignant	nodules	are	diffe-
rentiated	thyroid	cancer	of	the	follicular	epithelium	(papillary	and	
follicular).	Diagnosis	and	treatment	of	thyroid	carcinoma	requires	
a	multidisciplinary	approach.	First	Polish	guidelines	for	diagnosis	
and	treatment	of	thyroid	cancer	were	developed	in	1995	and	later	
in	2000	and	2006	updated.	Current	strategies	for	the	diagnosis	and	
treatment	of	 thyroid	cancer	 in	Poland	were	summarized	during	
IV	Thyroid	Cancer	Conference	in	Zakopane	last	year.	Herein	we	
discuss	the	guidelines	with	respect	to	Polish	experiences	in	diagnosis	
and	treatment	of	thyroid	cancer.
Fine	needle	aspiration	biopsy	remains	the	main	tool	to	asses	risk	
of	malignancy	in	thyroid	nodules.	The	newest	guidelines	under-
line	the	role	of	neck	ultrasound	to	assess	the	risk	of	malignancy	
and	to	select	most	suspicious	nodules	for	cytological	examination.	
Six	categories	of	diagnostic	classification	scheme,	which	apart	
from	malignant	 lesion	 introduces	 category	 of	 “suspicious	 for	
malignancy”	has	been	introduced	in	the	newest	guidelines.	In	
therapy,	complete	thyroidectomy	is	recommended	for	all	thyroid	
cancer	 except	 for	 papillary	 thyroid	 cancer	with	 diameter	 not	
exceeding	1	cm.	Later	on	those	patients	are	candidates	for	adju-
vant	radioiodine	treatment.	Adjuvant	radioiodine	treatment	is	
recommended	not	only	in	treatment	of	locally	advanced	cancer	
(lymph	node	metastases	or	primary	tumor	in	stage	pT3-4)	but	
also	in	patients	with	early	cancer	(pT2N0).
This	 recommendation	 is	based	on	good	 results	of	Polish	 clinical	
studies.	Development	of	new	positron	emission	tomography	centers	
enabled	to	recommend	PET/CT	examination	in	follow-up	of	patients	
with	suspicion	for	metastatic	disease.
W13:  
Intraoperative neuromonitoring of the recurrent 
laryngeal nerves may improve outcomes of surgery 
for well-differentiated thyroid cancer
M. Barczyński1, A. Konturek1, M. Stopa1, A. Hubalewska-
-Dydejczyk2, W. Nowak1
13rd Department of General Surgery, Jagiellonian University, Medical College, 
Kraków 
2Department of Endocrinology, Jagiellonian University, Medical College, Kraków
Background: The	recurrent	laryngeal	nerve	(RLN)	is	particularly	
prone	to	injury	during	thyroidectomy	in	a	case	of	extralaryngeal	
bifurcation	being	present	 in	approximately	one-third	of	patients	
near	the	inferior	thyroid	artery	or	ligament	of	Berry.
Aims: Meticulous	surgical	dissection	in	this	area	may	be	additio-
nally	facilitated	by	use	of	intraoperative	neuromonitoring	(IONM)	
to	 assure	 safe	 and	 complete	operation.	The	present	 study	was	
undertaken	to	test	this	hypothesis.
Material and methods: A	retrospective	cohort	study.	The	outco-
mes	of	 total	 thyroidectomy	with	 level	VI	 lymph	node	clearance	
for	well-differentiated	 thyroid	 cancer	 (WDTC;	pT1-3,N0-1,M0)	
were	 compared	between	225	patients	undergoing	 surgery	with	
IONM	(2005–2009)	and	225	patients	undergoing	surgery	without	
IONM	(2003–2005).	The	anatomical	 course	of	 the	extralaryngeal	
part	of	the	RLNs	were	analyzed	in	detail	in	each	operation.	Two	to	
4	months	after	surgery,	24-hour	thyroid	iodine-131	(I-131)	uptake	
was	measured.
Results: Among	patients	operated	with	vs.	without	 IONM	 the	
early	RLN	injury	rate	was	3.1%	vs.	6.7%	(p	=	0.01),	including	1.8%	
vs.	4.9%	(p	=	0.01)	of	temporary	nerve	lesions,	and	1.3%	vs.	1.8%	
of	permanent	nerve	events	(p	=	0.70),	respectively.	Extralaryngeal	
bifurcation	of	the	RLN	was	identified	in	65	(28.9%)	vs.	39	(17.3%)	of	
patients	operated	with	vs.	without	IONM,	respectively	(p	=	0.001).	
Mean	I-131	uptake	following	total	thyroidectomy	with	vs.	without	
IONM	was	0.61	±	0.38%	vs.	1.57	±	0.67%	(p	<	0.001).	I-131	uptake	
lower	than	1%	was	found	in	168	(74.7%)	vs.	54	(24%)	patients	ope-
rated	with	vs.	without	IONM,	respectively	(p	<	0.001).
Conclusions: Most	patients	with	WDTC	who	undergo	total	thy-
roidectomy	have	a	small	amount	of	residual	thyroid	tissue.	Use	of	
IONM	may	 improve	outcomes	of	 surgery	among	 these	patients	
by	both	 increasing	the	completeness	of	 total	 thyroidectomy	and	
significant	reduction	in	the	prevalence	of	temporary	RLN	injury.	
The	possible	mechanism	of	this	improvement	is	the	aid	in	dissection	
at	the	level	of	Berry’s	ligament	offered	by	IONM	which	enhances	
the	surgeon’s	ability	to	identify	a	branched	RLN,	and	allows	for	
reduction	of	traction	injury	and	neuropraxia	of	the	anterior	branch	
of	bifid	nerve.
167
Abstracts	
M
A
T
ER
IA
ŁY
 Z
JA
Z
D
O
W
E
PRESENT CHALLENGES IN THYROIDOLOGY
A. Hubalewska-Dydejczyk, J. Sowiński, M. Niedziela
W14:  
Treatment of metastatic thyroid cancer
M. Schlumberger
University Paris-Sud, Chair of the Department of Nuclear Medicine  
and Endocrine Oncology, Institut Gustave Roussy, France
The	large	majority	(>	85%)	of	patients	with	differentiated	thyroid	
carcinoma	(DTC)	and	many	(40%)	patients	with	medullary	thyroid	
carcinoma	 (MTC)	 can	be	 cured,	others	may	 survive	 for	decades	
despite	persistent	disease,	and	few	patients	with	advanced	disease	
may	require	novel	therapeutic	modalities.	Very	few	patients	with	
anaplastic	carcinoma	survive	over	one	year.
Distant	metastases	occur	in	5–10%	of	DTC	patients	and	one	third	
of	such	patients	can	be	cured	with	a	combination	of	levothyroxine	
treatment	at	doses	that	suppress	TSH	secretion,	radioiodine	treat-
ment	and	local	therapeutic	interventions.	Prognostic	indicators	for	
response	are	younger	age,	well	differentiated	thyroid	tumor,	small	
size	of	metastases,	high	uptake	of	radioiodine	and	low	uptake	of	
FDG	on	PET	scan.	Refractory	thyroid	cancer	patients	are	rare,	with	
an	estimated	annual	incidence	in	France	of	350	cases	that	is	stable	
with	time,	including	200	patients	with	DTC,	50	with	MTC	and	100	
patients	with	anaplastic	 thyroid	carcinoma.	 In	most	patients,	an	
initiating	carcinogenic	event	can	be	found	and	molecular	targeted	
therapy	can	be	given	with	a	scientific	rationale.	Patients	with	pro-
gressive	thyroid	cancer	should	preferably	be	included	in	prospective	
trials,	and	even	phase	I	trials	that	are	testing	the	newest	therapies	
should	be	 considered	 for	 these	patients,	 as	 these	protocols	may	
allow	early	identification	of	possibly	effective	drugs.	Progression	
should	be	defined	according	to	RECIST,	and	trends	in	serum	tumor	
marker	levels	are	not	sufficient	to	define	progression	or	to	assess	
tumor	response	during	treatment.
Although	response	criteria	in	these	contemporary	trials	differ	mar-
kedly	from	those	evaluating	cytotoxic	chemotherapy,	anti-tumour	
efficacy	of	these	agents	in	MTC	patients	is	likely	to	be	much	greater	
than	that	of	earlier	chemotherapies	(ORR	<	20%	with	chemothera-
py	using	5FU-DTIC).	Tumour	response	rates	are	similar	in	lymph	
nodes,	and	lung,	 liver	and	bone	metastases,	and	were	similar	 in	
patients	with	smaller	or	larger	tumour	masses.	Serum	calcitonin	and	
CEA	levels	decreased	during	treatment	in	most	patients,	and	this	
indicates	an	inhibition	of	the	RET	kinase,	but	it	may	be	not	paralleled	
by	a	decrease	in	tumour	volume.	Comparison	of	the	outcome	among	
these	compounds	is	at	the	present	time	not	possible.	Toxicity	was	
significant	and	led	to	dose	reduction	in	11–73%	of	patients	and	to	
drug	withdrawal	 in	7–25%.	There	were	no	unexpected	toxicities	
with	long-term	treatment.	However,	there	was	no	significant	une-
xpected	toxicity,	and	the	dose	of	l-thyroxine	treatment	had	to	be	
increased	in	the	majority	of	patients.	Benefits	demonstrated	with	
vandetanib	in	a	randomised	phase	III	trial	on	both	ORR	(44%	with	
long	lasting	responses)	and	PFS	(>	30.5	months	in	the	treatment	
arm	(median	not	reached)	versus	19.3	months	in	the	placebo	arm)	
counterbalance	toxic	effects	and	justify	its	use	in	MTC	patients	with	
progressive	or	symptomatic	disease	and	those	with	large	tumour	
burden.	Vandetanib	 is	available	 in	France	within	the	framework	
of	 an	Autorisation	Temporaire	d’Utilisation	 (ATU)	and	has	been	
labelled	in	the	USA	by	the	FDA.	Results	of	the	ongoing	phase	III	
trial	with	XL-184	are	expected	to	confirm	promising	results	obtained	
in	the	phase	I	trial	in	which	29%	of	35	patients	had	a	confirmed	
partial	 tumour	response.	There	 is	apparently	no	cross	resistance	
between	drugs.	Drugs	used	up	to	now	have	similar	mechanisms	of	
action,	all	being	anti-angiogenic	and	some	(including	vandetanib	
and	XL-184)	targeting	the	RET	tyrosine	kinase.	The	relative	role	of	
the	inhibition	of	each	target	or	of	their	combined	inhibition	is	cur-
rently	unknown,	but	because	axitinib	and	pazopanib	are	thought	
to	be	only	anti-angiogenic	drugs,	responses	suggest	that	the	anti-
-angiogenic	effects	of	these	compounds	might	play	an	important	
role.	Also,	responses	to	vandetanib	or	XL-184	have	been	observed	
in	patients	without	RET	mutation.	Even	among	patients	with	an	
RET	mutation,	tumour	responses	were	partial	and	were	observed	
in	only	a	fraction	of	patients.	This	may	indicate	that	targeting	RET	
may	not	be	sufficient	in	all	MTC	patients.	Future	studies	should	
explore	the	interest	in	effective	inhibition	of	the	MAPkinase	path-
way	downstream	of	the	RET	kinase,	and	of	other	pathways	such	
as	 the	PI3K-AKT-mTOR	pathway,	 and	 search	 for	other	 relevant	
targets	that	may	indicate	the	use	of	other	drugs.	In	DTC	patients,	
refractory	disease	is	defined	by	the	presence	of	at	least	one	tumour	
focus	without	any	uptake	of	radioiodine,	or	by	progressive	disease	
following	radioiodine	treatment	or	by	persistent	disease	after	six	
treatments	with	radioiodine.	Among	these	cancers,	histology	(papil-
lary	and	variants,	follicular	and	poorly	differentiated)	and	genetic	
defects	may	differ.	Anti-tumour	efficacy	of	these	agents	is	likely	to	
be	greater	than	that	of	earlier	chemotherapies	(using	doxorubicin	
or	taxanes),	with	partial	responses	observed	in	8–32%	of	patients	
and	long-term	stable	disease	in	at	least	another	half.	Comparison	
of	the	outcome	among	these	compounds	is	at	the	present	time	not	
possible,	but	the	response	rates	recently	reported	with	pazopanib	
and	lenvatinib	(E7080)	(around	50%)	seem	higher	than	in	previous	
reports.	It	also	appears	that	efficacy	may	differ	among	histological	
subtypes,	but	further	studies	are	needed	to	correlate	drug	efficacy	
with	the	genetic	defect	present	in	the	tumour.	Only	results	of	phase	
II	trials	have	been	reported;	a	phase	III	trial	(sorafenib	vs.	place-
bo)	is	ongoing	and	a	phase	III	trial	(lenvatinib	vs.	placebo)	will	
be	activated	in	2011,	as	well	as	several	phase	II	trials.	Also,	the	
stability	of	response	and	patterns	of	relapse	have	not	been	well	
characterised.	Drugs	used	up	to	now	have	similar	mechanisms	of	
action,	all	being	anti-angiogenic	and	some	targeting	the	kinases	
in	the	MAPkinase	pathway.	Tumour	responses	were	partial	and	
transient	and	were	observed	in	only	a	fraction	of	patients.	This	
may	 indicate	 that	 future	studies	should	use	drugs	targeted	to	
already	known	abnormalities	(such	as	an	inhibitor	of	the	BRAF	
kinase	in	patients	with	a	papillary	thyroid	carcinoma	harbouring	
the	mutated	BRAF),	and	search	for	other	relevant	targets.	Given	
the	 commercial	 availability	 of	 sorafenib	 and	 sunitinib,	 these	
agents	 have	 entered	 into	 clinical	 use	 for	 those	 patients	with	
progressive,	refractory	disease	who	are	not	suitable	candidates	
for	clinical	trials.	Finally,	trials	should	be	performed	in	patients	
with	anaplastic	thyroid	carcinoma,	using	drugs	directed	against	
angiogenesis	or	other	targets.	Further	trials	should	also	search	in	
MTC	and	DTC	patients	for	other	treatment	modalities,	including	
combination	or	sequential	treatment.	Recent	trials	have	shown	
that	inclusion	of	the	expected	number	of	thyroid	cancer	patients	
to	reach	statistically	significant	conclusions	is	possible	in	a	limited	
period	of	time,	and	this	may	be	further	improved	by	networks	
such	as	the	French	TUTHYREF	network	and	organisations	such	
as	the	Endocrine	taskforce	of	the	EORTC.
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W15:  
Selenium and the Thyroid
L. Duntas
Endocrine Unit, Evgenidion Hospital, University of Athens, Athens, Greece
The	trace	element	selenium	(Se),	which	is	in	the	form	of	selenocysteine	
(Seys)	inserted	in	selenoproteins,	such	as	deiodinases,	thioredoxins	
reductase	and	glutathione	peroxidase,	regulates	synthesis	and	intra-
conversion	of	T4	to	T3	as	well	as	redox	control.	Its	deficiency	has	been	
associated	with	thyroid	autoimmune	disease	and	goiter.	Se	is	abundan-
tly	present	in	the	thyroid,	made	available	via	the	main	transporter	of	
the	mineral,	Selonoprotein	P	(SeP),	deficiency	of	the	latter	leading	to	
disease.	In	addition,	recently	a	report	emerged	concerning	an	inheri-
ted	Secys	defect,	through	a	mutation	of	Secys	Binding	Protein,	which	
disrupts	thyroid	metabolism.	Se	compounds	in	the	form	of	selenome-
thionine	or	selenite	have	been	therapeutically	applied	in	patients	with	
autoimmune	thyroiditis	exhibiting	variable	results	as	regards	anti-TPO	
response	and	its	anti-inflammatory	effect,	the	discrepancy	of	the	results	
possibly	being	dependent	on	the	basal	Se	levels,	the	severity	of	disease	
and	the	duration	of	treatment.	Studies	have	also	reported	a	positive	
effect	 in	patients	with	 thyroid	associated	ophthalmopathy	 (TAO),	
containment	of	an	exacerbation	of	TAO	and	prolongation	of	the	re-
mission	phase	in	Graves’	disease	following	withdrawal	of	anti-thyroid	
treatment.	In	pregnant	women	with	autoimmune	thyroiditis	selenium	
administration	is	promising	in	reducing	the	incidence	of	miscarriage	
and	the	incidence	of	post-partum	thyroiditis.	As	a	micromineral	 in	
our	daily	diet,	Se	 is	of	considerable	 importance	 for	 the	prevention	
of	oxidative	stress	and	chemoprevention,	while	the	maintenance	of	
“selenostasis”	is	essential	for	preservation	of	human	health.
W16:  
New aspects of autoimmune thyroid diseases  
including Hashimoto’s and Graves’ disease
R. Gärtner
University of Munich, Germany
Thyroid	autoimmune	diseases	 include	chronic	 lymphocytic	 thy-
roiditis	with	and	without	goiter,	immunogenic	thyrotoxicosis	with	
or	without	thyroid	associated	ophthalmopathy	(Graves´disease),	
post-partum	 thyroiditis	 and	 the	very	 rare	 fibrosclerosing	 thyro-
iditis	 (Riedel’s	 thyroiditis).	Thyroid	 specific	 auto	 antibodies	 are	
frequently	detected	in	otherwise	healthy	subjects	(AIT)	and	affect	
around	16–20%	of	all	females	and	up	to	10%	of	males,	increasing	
with	age.	However	not	all	of	these	subjects	develop	an	autoimmune	
thyroid	disease	(AITD),	sometimes	only	after	decades	or	never.	In	
epidemiological	studies	 it	has	been	shown	that	80/100,000	males	
and	350/100,000	females	per	year	are	developing	hypothyroidism	
and	8/100,000	males	and	80/100,000	females	hyperthyroidism.	The	
main	cause	of	subclinical	or	overt	hypothyroidism	worldwide	 is	
Hashimoto´s	thyroiditis	and	no	longer	iodine	deficiency.
The	thyroid	obviously	is	the	organ	which	is	highly	vulnerable	to	
autoimmune	diseases	(AITD).	They	develop	due	to	the	complex	
interplay	of	genetic,	environmental,	and	endogenous	factors,	and	
a	 specific	 combination	 is	 required	 to	 initiate	and	promote	auto-
immunity.	Seven	genes	had	been	identified	that	contribute	to	the	
etiology	of	AITD.	HLA-DR3	is	associated	with	Graves´disease	and	
Hashimoto´s	disease.	Non-MHC	genes	that	confer	susceptibility	
can	be	classified	into	two	groups:	 immune-regulatory	genes	like	
CD40,	CTLA-4,	FCRL3,	 IL-2-R	and	PTPN22	and	 thyroid	specific	
genes,	the	thyroglobulíne	and	TSH-receptor	genes.
Environmental	factors	that	trigger	the	AIT	are	stress,	unopposed	
high	 estrogens	 by	progesterone,	 high	 iodine	 intake,	 selenium	
deficiency,	pollutants,	 infectious	diseases,	and	certain	drugs	 like	
amiodarone	or	 interferon-alpha.	When	the	thyroid	cell	becomes	
the	target	of	autoimmunity	it	interacts	with	the	immune	system,	
releases	 cytokines,	 growth	 factors,	 adhesion	molecules	which	
might	promote	the	progression	of	the	disease.	A	cooccurrence	of	
AIT	with	differentiated	 thyroid	 cancinoma,	 especially	papillary	
thyroid	cancer	(PTC)	has	repeatedly	reported.	It	is	still	a	matter	of	
debate	whether	the	chronic	lymphocytic	reaction	is	trigged	by	the	
malignant	cells	or	vice	versa.	A	higher	frequency	of	malignancy	of	
neoplastic	thyroid	nodules	has	been	shown	in	several	studies	but	
not	confirmed	by	others.	The	thyroglobuline	antibodies	seem	to	be	
unspecific,	however	TPO-antibodies	are	specific,	their	activity	is	as-
sociated	with	the	activity	of	the	disease,	are	complement	activating,	
induce	the	antigen-presentation	to	autoaggressive	T-cells,	activate	
NK-cells	but	do	not	inhibit	the	enzyme	activity.	TSH-receptor	an-
tibodies	(TRAb)	either	stimulate	the	thyroid	function	or	only	bind	
or	inhibit	the	receptor.
Although	the	thyroid	is	the	most	common	target	of	autoimmunity,	
other	organs	like	islet	cells,	adrenal,	gastric	parietal	cells,	melanocy-
tes	of	the	skin,	pituitary	cells,	or	gonadal	cells	also	might	be	affected	
although	to	less	degree.	This	however	has	to	be	kept	in	mind	for	
patients	care.	It	also	is	important	to	consider	family	screening	for	
thyroid	diseases	if	one	member	has	been	identified	to	suffer	from	
AITD	as	 it	has	been	 shown	 that	 7.5%	of	 children	within	 every	
5	years	from	mothers	with	AITD	develop	thyroid	specific	antibodies.
Females	in	child	bearing	age	with	positive	thyroid	specific	antibo-
dies	but	normal	 thyroid	function	(AIT)	exhibit	a	2–3	fold	higher	
incidence	of	early	abortion	and	premature	delivery.	These	females	
have	to	be	treated	early	with	L-Thyroxine	to	keep	TSH	within	the	
low	normal	range	and	a	selenium	supplementation	might	reduce	
the	exacerbation	of	AITD	after	delivery.	In	contrast	it	is	not	justified	
to	supplement	L-Thyroxine	in	subjects	with	AIT	but	normal	thyroid	
function	as	it	has	not	been	shown	by	controlled	trials	to	influence	
of	 the	 course	of	 the	disease.	These	 subjects	might	benefit	 from	
a	selenium	supplementation	and	avoidance	of	other	environmental	
factors	known	to	trigger	or	promote	the	disease.	In	Graves’	disease,	
methimazole	is	the	treatment	of	choice	for	about	one	year	and	the	
decrease	of	TRAb	predict,	whether	thereafter	the	disease	will	re-
lapse	or	not.	If	TRAb	is	above	10	U/L	the	probability	of	a	relapse	is	
more	than	50%	and	thyroidectomy	either	by	surgery	or	radioiodine	
treatment	is	recommended.
W17:  
Thyroid dysfunction associated with the adminis-
tration of medications, including amiodarone and 
tyrosine kinase inhibitors
A. Hubalewska-Dydejczyk
The Chair and Department of Endocrinology, Jagiellonian University,  
Medical College
For	 the	 last	 several	decades	 some	drugs	have	been	used	 in	 the	
nonthyroidal	disease	treatment	which	present	clinically	relevant	
side	effects	on	thyroid	function.	Some	of	them	influence	thyroid	
hormone	metabolism	changing	the	required	supplementation	dose	
of	l-thyroxin	in	patients	on	the	replacement	therapy.	Others	affect	
hormone	synthesis	leading	to	the	development	of	primary	hypo-
thyroidism.	The	immunomodulation	medications	and	these	used	
in	anti-cancer	therapy	can	also	cause	hypo-	and	hyperthyroidism	
with	not	 fully	 known	 immunological	 and	non-immunological	
mechanisms.
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The	best	known	are	side	effects	associated	with	administration	
of	 amiodarone	 affecting	 approximately	 15	 to	 20%	 of	 treated	
patients.	Although,	 in	 spite	 of	many	 studies,	 its	 influence	 on	
thyroid	function	remains	unclear	because	of	the	process	com-
plexity.	The	least	controversial	is	treatment	of	hypothyroidism	
caused	by	amiodarone,	but	some	doubts	may	arise	concerning	
the	selection	of	the	optimal	l-thyroxin	dose	in	case	of	sustained	
high	values	of	both	TSH	and	FT4.	Amiodarone-induced	thyro-
toxicosis	 (AIT),	more	often	observed	 in	 iodine-deficient	areas,	
may	occur	at	any	time	from	the	drug	implementation,	and,	what	
is	most	important	causes	deterioration	of	the	patient’s	cardiac	
condition.	There	are	3	types	of	AIT:	type	I	is	a	consequence	of	
a	large	amount	of	iodine	load	in	patients	with	thyroid	pathology,	
type	II	is	a	result	of	direct	toxic	effect	of	iodine/amiodarone	on	
the	 thyroid	 cells	 causing	destructive	 thyrotoxicosis,	 and	 type	
III	is	a	mixed/indefinite	form	which	may	have	features	of	both	
AIT	subtypes.	Whereas	some	AIT	cases	are	mild,	others	can	be	
severe	with	a	fatal	outcome.	The	most	controversial	is	recogni-
tion	of	AIT	subtype	and	to	find	the	best	treatment	method	with	
the	assessment	of	indications	and	an	optimal	time	for	surgery.
Tyrosine	kinase	inhibitors	(TKI)	are	increasingly	being	introduced	
for	the	treatment	of	cancer,	and	a	lot	of	clinical	trials	have	been	con-
ducted	to	assess	their	effectiveness	in	many	different	tumour	types.	
According	to	the	literature	hypothyroidism	may	occur	in	up	to	68%	
of	TKI	treated	patients	and	thyrotoxicosis	is	observed	in	more	than	
20%	of	cases.	During	the	course	of	TKI	treatment	hypothyroidism	
requires	supplementation	therapy	with	individually	matched	dose	
of	l-thyroxine,	and	the	open	question	remains	whether	hyperthy-
roidism	is	an	indication	for	TKI	therapy	interruption,	temporary	
discontinuation	or	lowering	the	dose	of	the	drug.
Poster session
P1:  
Medullary thyroid carcinoma — future possibilities 
of diagnosis and therapy
A. Jabrocka-Hybel, D. Pach, A. Sowa-Staszczak,  
M. Tomaszuk, A. Hubalewska-Dydejczyk
Chair and Department of Endocrinology, Jagiellonian University, Medical College
Medullary	 thyroid	 cancer	 (MTC)	 is	 an	uncommon	malignancy	
arising	from	the	parafollicular	C	cells.	Its	low	incidence	has	limited	
both	widespread	clinical	expertise	and	definitive	large	randomized	
clinical	trials.	Epidemiological	studies	have	shown	that	during	the	
past	30	years	neither	a	change	in	stage	at	diagnosis	nor	improve-
ment	in	survival	has	occurred	for	MTC	patients.	Current	therapy	
of	metastatic	patients	is	not	fully	successful	and	searching	for	new	
therapies	is	necessary	based	on	tumor	biology	(targeted	therapy),	
and	based	on	 the	 interactions	between	 thyroid	 cancer	 cells	 and	
their	microenvironment	 (inhibitors	of	 tumour	angiogenesis).	 In	
recent	years,	the	clinical	validation	of	molecular	targeted	therapies	
has	been	one	of	the	most	exciting	developments	in	cancer	research	
and	MTC	represents	a	promising	model.	It	is	well	known	that	in	
MTC,	the	tyrosine	kinase	RET	(RET-TK)	receptor	and	its	signal	trans-
duction	pathways,	lead	to	subsequent	neoplastic	transformation.	
Several	strategies	aimed	at	blocking	the	activation	and	signaling	of	
RET	have	been	preclinically	tested.	The	most	advanced	results	have	
been	obtained	by	competitive	inhibition	of	RET-TK	activity	by	tyro-
sine	kinases	inhibitors	(TKI).	However,	although	the	inhibition	of	
the	RET	pathway	is	actually	one	of	the	most	studied	for	therapeutic	
purposes,	other	signal	transduction	pathways	have	been	recognized	
to	 contribute	 to	 the	growth	and	 functional	activity	of	MTC	and	
are	 considered	attractive	 therapeutic	 targets	 (mTOR	 inhibitors).	
To	date,	surgery	represents	the	only	curative	treatment	of	MTC.	
Despite	promising	initial	results,	studies	on	targeted	agents	are	in	
early	stages	and	several	issues	regarding	preclinical	evaluations	and	
clinical	trials	of	new	targeted	agents	in	MTC	are	still	unresolved.	
New	hopes	 are	 concerned	with	 radionuclide	 targeted	 therapy,	
especially	with	radiolabelled	gastrin/CCK	peptides.
A	major	effort	needs	to	be	made	by	endocrinologists,	oncologists	and	
nuclear	medicine	doctors	to	refer	their	patients	for	multi-institutio-
nal	trials	in	order	to	optimize	them,	perform	translational	studies	
and	expedite	the	availability	of	novel	beneficial	selective	therapies.
P2:  
The co-existence of papillary thyroid carcinoma and 
primary hyperparathyroidism in a female patient 
with toxic nodular goitre
M. Kurowska, J.S. Tarach, J. Malicka, J. Kijek
Department of Endocrinology, Medical University of Lublin
Introduction: The	 reason	why	 differentiated	 thyroid	 can-
cer	 and	 primary	 hyperparathyroidism	 co-occur	 remains	
controversial.	 According	 to	 some	 authors,	 their	 coexistence	
is	 accidental,	while	 others	 claim	 that	 it	 is	 caused	by	 a	high	
concentration	of	endogenous	calcium	and	calcitonin.	Nodular	
goitre	 is	 found	in	22%	to	70%	patients	with	primary	hyper-
parathyroidism.	 The	 incidence	 of	 carcinoma	 from	 thyroid	
follicular	cells	in	patients	with	primary	hyperparathyroidism	
is	estimated	at	3.1	to	15%.
Aim: To	present	a	 rare	 case	of	 co-existence	of	papillary	 thyroid	
carcinoma	and	primary	hyperparathyroidism	in	a	female	patient	
with	toxic	nodular	goitre.
Case report: The	patient,	aged	75,	has	been	treated	for	osteoporosis	
for	several	years.	A	thyroid	ultrasound	showed	a	toxic	nodular	
goitre.	A	thyroid	hormone	test	confirmed	hyperthyroidism.	An	
FNAB	of	one	of	the	focal	thyroid	lesions	showed	tumour	tissue	
composed	of	oxyphil	cells.	Hypercalcemia	was	revealed	in	a	scre-
ening	blood	test.	A	clinical	examination	confirmed	the	diagnosis	
of	primary	hyperparathyroidism	(hypercalcemia,	hypophospha-
temia,	hypercalciuria	and	an	elevated	PTH	level).	An	adenoma	
was	found	in	the	upper	right	parathyroid	in	MIBI	scintigraphy.	
The	patient	underwent	 a	 thyroidectomy	and	 a	parathyroidec-
tomy	 simultaneously.	 A	 post-operative	 histopathological	 test	
showed	 the	 following:	 a	papillary	 thyroid	 carcinoma,	 invasion	
of	 the	cancer	 into	the	thyroid	capsule	and	 local	adipose	tissue,	
lymphangiosis	carcinomatosa	and	a	parathyroid	adenoma.	There	
were	complications	 in	the	post-operative	period	in	the	form	of	
hypoparathyroidism	with	tetany,	hypothyroidism	and	paresis	of	
the	left	part	of	the	larynx.
Conclusion: The	co-existence	of	follicular	thyroid	carcinoma	with	
parathyroid	carcinoma	is	rare,	but	it	needs	to	be	taken	into	consi-
deration	in	diagnosing	thyroid	diseases	which	often	accompany	
primary	hyperparathyroidism.
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P3:  
Thyroid metastases from a breast cancer diagnosed 
by fine-needle aspiration biopsy. Case report and 
overview of the literature
K. Łącka1, D. Breborowicz2, A. Uliasz3, M. Teresiak4
1Department of Endocrinology, Metabolism and Internal Medicine, University  
of Medical Sciences, Poznan, Poland 
2Department of Tumor Pathology, Oncology Center, Poznan, Poland 
3Student’s Scientific Society, University of Medical Sciences, Poznan, Poland 
4Department of Oncology Surgery, Oncology Center, Poznan, Poland
Key words: thyroid	metastasis,	breast	cancer,	markers,	fine-needle	
aspiration.
Objective: Intrathyroid	metastases	are	uncommon	in	cytology	
practice.	We	report	a	case	of	metastatic	lesion	in	the	thyroid	from	
breast	carcinoma	which	was	recognized	in	fine	needle	aspira-
tion	 biopsy	 (FNA)	 and	 confirmed	 by	 immunohistopathology.	
In	 addition,	we	provide	 an	 overview	 of	 literature	 describing	
similar	cases.
Study design: The	patient	was	a	54-year	old	woman	with	a	large,	multi-
nodular	goiter	and	bilaterally	enlarged	lymph	nodes	in	supraclavicular	
areas.	Fourteen	years	earlier	she	had	undergone	radical	mastectomy	
followed	by	chemo-	and	radiotherapy	due	to	breast	carcinoma.
Results:	FNA	of	thyroid	nodules	showed	metastatic	breast	carcino-
ma	and	was	followed	by	total	strumectomy	and	lymphadenectomy.	
Histological	reassessment	of	the	surgical	specimens	of	the	thyroid	
gland	as	well	as	neck	lymph	nodes	revealed	multiple	breast	meta-
stases.	This	was	strongly	confirmed	by	immunochemistry,	which	
revealed	the	positive	staining	for:	ER,	PgR	and	HER2	as	well	as	for	
CKMNF	116,	CK7,	and	CEA,	and	negative	staining	for:	thyroglo-
bulin,	TTF1,	calcitonin,	chromogranin	and	CK20.
Conclusion: In	view	of	 the	 above,	we	deduce	 that	 every	new	
aggregate	 in	 the	 thyroid	 in	patient	with	even	distant	history	of	
cancer	should	be	considered	as	potentially	metastatic	until	proved	
otherwise.	FNA	could	be	helpful	 in	the	diagnosis	of	 the	thyroid	
metastatic	lesion.
P4: Hormonal activity of the thyroid gland in women 
after mastectomy treated with radiotherapy  
— personal research
A. Majkowska-Młynarczyk1, M. Kinalski2
1Faculty of Health — Higher School of Economy and Law Kielce, Provincial 
Specialist Hospital, Kielce 
2Provincial Specialist Hospital–Gynecological Department, Białystok
There	is	ongoing	debate	about	the	link	between	breast	diseases	and	
hormonal	function	of	thyroid	gland.	Less	information	is	present	
about	influence	of	breast	cancer	treatment:	mastectomy,	radiothera-
py,	hormonal	therapy	or	combined	therapy	on	thyroid	dysfunction.
This	work	presents	influence	of	aggressive	form	breast	cancer	
treatment	such	as	mastectomy	and	radiotherapy	combined	with	
chemotherapy	on	change	in	thyroid	function	just	after	finishing	
therapy	and	after	five	and	10	years	from	this	moment.	173	wo-
men	(mean	age	56)	were	examined	divided	into	breast	cancer	
group	—	97	women	and	control	group	—	76	healthy	women.	
27%	women	with	breast	cancer	were	treated	with	mixed	beam	
photon-electron	radiotherapy	fractionated	in	2.25	Gy	doses	to	
cumulative	dose	45	Gy.
Thyroid	function	and	morphology	were	diagnosed	with:
1.	 Fine	needle	 aspiration	biopsy	 and	USG	with	dynamic	 color-
-doppler	mode
2.	Measurement	of	hormone	concentrations:	TSH,	FT3,	FT4
3.	Levels	of	 antibodies:	 against	 thyroperoxidase	and	antithyro-
globulin
Results	show	that	in	the	group	after	radiotherapy	levels	(arithmetic	
mean)	of	anty-TPO	are	two	times	higher	in	the	group	after	radiothe-
rapy.	In	46%	of	patients	levels	of	anty-TPO	were	higher	but	median	
levels	don’t	show	statistical	difference.	Antithyroglobulin	antibodies	
were	higher	in	20%	of	women	treated	with	radiotherapy.	There	was	
no	influence	of	radiotherapy	on	thyroid	hormone	concentrations.	
Papillary	carcinoma	of	thyroid	gland	was	found	in	two	patients,	
which	is	7%	of	patients	treated	with	radiotherapy.
Conclusions:	1.	Previous	breast	cancer	treatment	(chemotherapy,	
radiotherapy)	results	in	increased	levels	antithyroperoxidase	anti-
bodies.	2.	Radiotherapy	of	breast	cancer	can	increase	prevalence	of	
thyroid	cancer.	3.	Women	after	successful	breast	cancer	treatment	
have	high	 levels	of	 thyroid	antibodies.	 It	 can	 suggest	 that	 after	
years	it	could	manifest	with	laboratory	and	clinical	signs	of	thyroid	
insufficiency.
P5: Thyroid lymphoma — diagnostic struggle
A. Łuczycki1, Ł. Koperski3, M. Januszewicz3, J. Pachucki1
1Department of Internal Medicine and Endocrinology, Medical University, 
Warsaw 
2Department of Pathological Anatomy, Center for Biostructure Research, Medical 
University of Warsaw 
3II Department of Clinical Radiology, Medical University, Warsaw
We	present	a	case	report	to	dispute	diagnostic	difficulties	in	patients	
suspected	for	thyroid	lymphoma.
This	68-yo	man	was	sent	to	ER	from	endocrinology	clinic	due	to	
symptoms	of	upper	airway	obstruction	and	asymmetrical	rapid	(few	
weeks)	increase	in	goiter	size.	Patient’s	symptoms	were	obscured	by	
severe	COPD	which	required	several	admissions	over	last	few	years.	
He	was	previously	followed	for	years	due	to	non-toxic	MNG	but	
FNAB	was	probably	never	done	before.	Three	months	earlier	when	
large	B-cell	lymphoma	was	diagnosed	after	removal	left	testicular	
tumor	 (about	 8	 cm)	 and	endocrine	 consultation	 recommended	
methimazole	 for	 thyrotoxicosis	although	no	clinical	 suspicion	of	
thyroid	malignancy	was	appreciated.	At	admission	the	thyroid	was	
hard	and	tender	but	without	redness,	surrounding	soft	tissue	edema	
or	pathological	lymphatic	nodes	on	palpation.	Thyroid	ultrasound	
suggested	multinodular	goiter	with	nodule	conglomerates	up	to	
4.5	cm.	The	FNAB	of	dominant	nodule	suggested	thyroiditis.	Patient	
was	send	home	on	low	dose	steroids.	Due	to	diagnostic	bias	three	
consecutive	FNAB	were	perform	by	 three	pathologists	and	 two	
of	 them	described	 inflammation	and	one	atypical	cells	probably	
lymphoid	 in	origin	 (flow	cytometry	was	non	diagnostic	due	 to	
low	leukocyte	count).
Symptoms	did	not	improve	and	total	body	CT	showed	oval	areas	
of	infiltration	in	liver	and	lung	very	suggestive	for	malignancy.	
Moreover	tracheo-nodal	or	tracheo-thyroid	fistula	was	suspected	
based	on	CT	and	bronchoscopy	 (biopsy	of	 tracheal	 exophytic	
mass	was	 non-diagnostic).	 FNAB	 of	 liver	 lesion	was	 highly	
suggestive	for	lymphoma	and	patient	received	Dexamethasone	
and	one	course	of	COP	chemotherapy.	Follow	up	bronchoscopy	
showed	increase	in	size	of	exophytic	mass	but	biopsy	was	again	
non-diagnostic.	 Patient	was	 sent	 home	 and	 further	 chemo-
therapy	was	withheld	 awaiting	 clarification	of	 single	positive	
sputum	smear	for	AFB	(MTb-PCR	negative).	Four	months	from	
stepping	into	ER,	shortly	after	following	admission	patient	died	
probably	as	a	result	of	pneumothorax	and	worsened	respiratory	
failure.	Thyroid	FNAB	has	limited	value	in	diagnosing	of	thyroid	
lymphoma.
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P6:  
Cigarette smoking as a risk factor for differentiated 
thyroid cancer
E. Przybylik-Mazurek, D. Pach, S. Kuźniarz-Rymarz,  
M. Tracz-Bujnowicz, A. Hubalewska-Dydejczyk
Department of Endocrinology, Jagiellonian University Medical College, Krakow
The aim of the study was	to	assess	the	association	of	tobacco	smo-
king	with	differentiated	thyroid	cancer	(DTC).
Material and methods: The	“case-control”	study	was	performed	in	
232	patients	with	DTC:	in	31	men	(mean	age	60.2	±	12	years)	and	
201	women	(mean	age	50.7	±	13.1	years)	and	in	342	healthy	sub-
jects:	58	men	(mean	age	60.2	±	12	years)	and	285	women	(mean	age	
53.4	±	14.3	years).	Interviews	regarding	information	of	tobacco	smo-
king	were	conducted	using	the	same	questionnaire.	To	assess	the	rela-
tive	risk	of	DTC	logistic	regression	analysis	adjusted	to	age	was	used.
Results:	There	was	decreased	risk	of	DTC	among	current	smokers	
(OR	=	0.61;	95%	CI:	0.35–1.06)	and	increased	in	former	smokers	
(OR	=	1.60;	95%	CI:	1.08–2.36).	There	was	increased	risk	of	DTC	in	
smokers	above	20	cigarettes	per	day	(OR	=	1.73;	95%	CI:	0.57–5.28)	
and	in	smokers	with	age	of	initiation	of	smoking	below	18	years	of	
age	(OR	=	1.27;	95%	CI:	0.67–2.40).
Conclusions: Current	smoking	seems	not	to	be	a	risk	factor	of	DTC.	
Increased	risk	of	DTC	in	former	smokers	may	result	from	coexistence	
of	other	factors	and	it	needs	further	studies.
P7:  
Primary thyroid lymphoma, a rare thyroid disease 
with a good prognosis
E. Przybylik-Mazurek, S. Kuźniarz-Rymarz, D. Pach,  
M. Buziak-Bereza, A. Hubalewska-Dydejczyk
Department of Endocrinology, Jagiellonian University Medical College, Krakow
Background: Primary	thyroid	lymphoma	is	an	uncommon	tumour	
representing	1–5%	of	all	thyroid	malignancies.
The	aim	of	the	study	was	to	review	our	experience	and	management	
of	primary	thyroid	lymphoma	and	to	discuss	the	diagnostic	and	
therapeutic	considerations.
Methods: Five	women	and	one	men	with	primary	thyroid	lym-
phoma	were	observed	in	our	department	from	1995.	The	clinical	
course	and	pathological	 spectrum	of	 this	disorder	 affecting	 the	
thyroid	gland	were	reviewed.
Results: Clinical	symptoms,	including	a	rapidly	enlarging	painless	
neck	mass,	dysphagia	 and	dyspnoea	were	present	 in	 all	 cases.	
Nodular	 goiter	was	 observed	 in	 three	patients,	 thyrotoxicosis	
and	 subclinical	hypothyreosis	 in	 course	of	Hashimoto’s	disease	
were	observed	in	two	cases	at	the	time	of	diagnosis.	Fine-needle	
aspiration	cytology	(FNAC)	was	performed	in	all	patients.	Initial	
diagnosis	of	thyroid	lymphoma	was	established	only	in	one	patient.	
Three	patients	were	diagnosed	as	anaplastic	or	follicular	thyroid	
carcinoma,	in	two	cases	FNAC	was	non	diagnostic.	All	of	the	patients	
underwent	an	 initial	surgical	procedure;	 in	one	case	emergency	
debulking	of	the	tumour	in	the	course	of	acute	airway	obstruction	
with	transient	tracheostomy	was	performed.	Five	patients	received	
combination	 chemotherapy	with	or	without	 irradiation.	A	 final	
diagnosis	of	thyroid	B-cell	non-Hodgkin’s	lymphoma	was	confir-
med	in	all	these	patients.	Overall	survival	and	disease	free	survival	
during	follow-up	was	100%.
Conclusion: The	diagnosis	of	primary	thyroid	lymphoma	should	
be	considered	when	dealing	with	rapidly	growing	goiter.	The	role	
of	FNAC	is	limited	and	surgical	intervention	is	needed	for	a	confir-
matory	diagnosis	of	thyroid	lymphoma	using	combined	histology	
and	immunohistochemistry.	A	combination	of	chemotherapy	and	
irradiation	is	the	mainstay	treatment	which	improves	prognosis.
P8: Contribution of different genes in genetic  
predisposition to Graves’ disease (GD)  
— multiple logistic regression approach
B. Jurecka-Lubieniecka1, E. Paliczka-Cieślik1, D. Kula1,  
A. Król1, J. Krajewska1, A. Pawlaczek1, T. Bednarczuk2,  
R. Płoski3, J. Polańska4, B. Jarząb1
1Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice 
Branch Poland 
2Department of Endocrinology, Medical University of Warsaw, Poland 
3Department of Medical Genetic, Medical University of Warsaw, Poland 
4Institute of Automatic Control, Silesian University of Technology, Gliwice, 
Poland
Objectives: The	purpose	of	the	study	was	to	evaluate	interactions	
between	genes	involved	in	development	of	GD,	as	well	as	an	at-
tempt	to	correlate	different	genotypes	with	specific	phenotypes.	
An	 influence	of	possible	genetic	 risk	 factors	on	GD	disease	was	
investigated	based	on	the	set	of	selected	genes	such	as	TNF,	LTA,	
CTLA,	HLA-DRB1-03,	TG,	CD40,	IL-10,	IL4,	OAS,	NFKB,	LYP,	RTSH.
Methods: The	study	population	consisted	of	1951	patients	including	
735	GD	subjects.	Due	to	the	missing	data	a	Bayesian	approach	has	
been	applied	followed	by	a	multivariate	logistic	regression.
Results: Four	genes	were	indicated	as	plausibly	characteristic	for	
GD	in	Polish	population:	TNF,	CTLA,	HLA-DRB1-03	and	NFKB	(the	
effect	of	remaining	gene	mutations	was	estimated	as	insignificant).
In	order	to	distinguish	the	genetic	heterogeneity	in	the	dataset,	GD	
patients	were	divided	into	several	subsets	according	to	gender,	age	
and	age	of	onset	of	the	disease.	The	presence	of	mutation	in	TNF,	
LTA	and	HLA	genes,	on	the	basis	of	OR	value	was	related	to	the	
age	of	disease	onset,	while	TG	mutations	may	be	responsible	for	
female	preponderance	of	GD.
Conclusions:	 The	 study	allowed	 to	 initially	 select	genes	predi-
sposing	the	subgroups	of	patients	according	to	the	age	of	onset	of	
the	disease	—	TNF,	LTA	and	HLA	genes	and	gender	(TG	genes).	It	
constitutes	an	individual	approach	towards	the	patients	with	GD.
Grant No N519 579938
Table I. Logistic regression estimates of risk factors for GD
Gene Mean (regr. coef.) Stand. dev. Cred. 95% int. Odds ratio (OR = exp(coef.)) p-value
TNF 0.3321 0.1348 (0.0690–0.6002) 1.39 0.0074
CTLA 0.3813 0.0824 (0.2186–0.5430) 1.46 < 0.0001
HLA-DRB1-03 0.7117 0.1745 (0.3740–1.0520) 2.04 < 0.0001
NFKB 0.2980 0.0770 (0.1501–0.4473) 1.35 < 0.0001
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P9:  
Comparison of thyroid volume and goiter measured 
by means of ultrasonography and SPECT with use  
of 131I in smokers and non-smokers
M. Gierach, R. Junik
Department of Endocrinology and Diabetology with the Laboratory of Nuclear 
Medicine, University Hospital No. 1 in Bydgoszcz
Introduction: The	aim	of	 the	study	was	 to	estimate	 the	volume	
of	the	goiter	by	means	of	US	and	131I-SPECT	and	to	estimate	the	
influence	of	nicotine	on	thyroid	volume	according	to	patients’	sex.
Material and methods: The	study	group	contained	50	patients	with	
goiter,	where	the	volume	of	the	thyroid	was	evaluated	with	use	of	
US	and	131I-SPECT.	The	control	group	contained	30	patients	with	
normal	volume	of	the	thyroid	gland	shown	by	US	and	131I-SPECT.	
The	patients	from	the	examined	and	control	group	were	divided	
into	two	subgroups	—	smokers	and	non-smokers.	US	of	the	thyroid	
gland	was	made	by	means	of	an	ALOKA	SSD	500	device.	SPECT	was	
performed	by	means	of	a	single-headed	gamma	camera	by	Diacam.
Results: The	average	volume	of	thyroid	gland	measured	by	131I-
-SPECT	was	significantly	larger	according	to	US	in	the	examined	
and	control	group	in	smokers	and	non-smokers.	We	did	not	show	
statistically	significant	correlations	between	levels	of	iodine	uptake	
and	volumes	of	goiter	evaluated	by	US	examination	together	with	
131I	scintigraphy.
Conclusions:	Significant	differences	in	average	values	of	thyroid	
volume	between	 smokers	 and	non-smokers	were	not	observed,	
which	might	suggest	a	lack	of	goitrogenic	activity	of	tobacco	smoke	
or	indicates	a	potential	goitrogenic	influence	not	significant	enough	
in	the	examined	group.
P10:  
Thyroid hormone profile and NT-proBNP levels  
in the assessment of heart failure severity
A. Jabrocka-Hybel1, B. Głowa2, W. Lenda-Tracz2, J. Hybel3, 
P. Kusak4, D. Czarnecka4, A. Hubalewska-Dydejczyk1
1Department of Endocrinology, Jagiellonian University School of Medicine, 
Kraków, Poland 
2Nuclear Medicine Unit Endocrinology Department, Jagiellonian University, 
Medical College, Cracow, Poland 
3Department of Internal Medicine and Cardiology, Jędrzej Śniadecki Hospital  
in Nowy Sącz 
41st Department of Cardiology and Hypertension, Jagiellonian University Medical 
College, Kraków, Poland
A	low	T3	syndrome	was	described	in	patients	with	heart	failure	
(HF),	and	it	appears	to	be	associated	with	adverse	outcome,	repre-
senting	an	independent	predictor	of	mortality.	On	the	other	hand,	
an	elevation	of	brain	natriuretic	peptides	(BNP	and	NT-proBNP)	
may	represent	a	warning	signal	for	future	cardiovascular	disease	
and	may	be	 an	 early	marker	 of	 diastolic	 dysfunction.	Arterial	
hypertension	(AH)	and	diabetes	mellitus	type	2	(DM2)	are	known	
risk	factors	for	the	development	of	diastolic	dysfunction	and	HF.
The	aim	of	our	study	was	tested	the	hypothesis	that	impaired	levels	
of	thyroid	hormone	profile	(especially	FT3	and	rT3)	assessed	toge-
ther	with	NT-proBNP	are	better	predictive	marker	than	assessed	
separately.	Assessment	of	these	two	parameters	could	be	sufficient	
to	determine	asymptomatic	cardiac	impairment.
Fifty	patients	were	qualified	to	our	study	(17	with	HF	—	group	I,	
17	with	DM2	and	AH	—	group	II	and	16	healthy	volunteers).	In	
each	patient	thyroid	hormone	profile	(TSH,	FT4,	FT3	and	rewers	
T3)	and	NT-proBNP	were	assessed.
Echocardiography	was	performed	according	to	the	Polish	Cardiac	
Society	standards.	Radioisotope	ventriculography	was	performed	
with	using	gamma	camera	E.CAM	180	(Siemens).
No	 statistically	 significant	differences	 in	TSH	and	FT4	between	
groups	were	observed.	FT3	was	lowest	in	group	I	(p	<	0.05)	and	
negative	correlation	with	NT-proBNP	(R	=	–0.47,	p	<	0.05)	and	
positive	with	ejection	fraction	(EF)	of	the	left	ventricle	(R	=	0.25,	
p	<	0.05)	were	observed.	FT3	in	group	II	also	was	lower	than	in	con-
trol	group	but	results	were	not	statistically	significant.	Systolic	heart	
failure	with	low	ejection	fraction	(EF)	was	observed	in	all	patients	
in	the	group	I.	Diastolic	heart	failure	with	E/A	index	below	1,	but	
in	two	patients	with	higher	E/E’	index	and	left	atrium	enlargement,	
was	observed	in	the	group	II.
Results	were	confirmed	in	radioisotope	ventriculography.	No	chan-
ges	in	systolic	and	diastolic	function	were	observed	in	the	control	
group.	Results	of	rT3	are	currently	under	development.
Assessment	of	thyroid	hormone	levels	in	the	patients	with	HF	could	
give	more	information	about	severity	of	the	disorder.	Echocardiogra-
phy	or	radioisotope	ventriculography	should	be	performed	 in	 the	
patients	with	AH	and	DM2	for	searching	cardiac	diastolic	dysfunction.
P11:  
The patient with adrenal insufficiency and Graves-
-Basedow’s disease
R. Junik, A. Nowicka
Department of Endocrinology and Diabetology with the Laboratory of Nuclear 
Medicine, University Hospital No. 1 in Bydgoszcz
A	42-year-old	patient	was	admitted	 to	 the	Department	 in	April	
2011	in	severe	general	condition	due	to	hipermetabolic	crisis.	The	
patient	had	no	previous	medical	history	of	any	endocrine	disease.	
Over	the	previous	few	weeks	he	had	lost	about	10	kg	of	weight	
and	had	observed	growing	weakness,	nausea,	vomiting,	abdominal	
pain	and	darkening	of	the	skin.	On	the	surgical	ward	he	had	been	
diagnosed	for	suspected	ulcer	disease.	In	laboratory	tests,	which	
were	performed	at	admission	we	observed	TSH	<	0.0025	uU/ml,	fT4	
2.11	ng/dl,	fT3	2.46	pg/ml,	TRAb	3.44	IU/l	and	features	of	autoim-
mune	thyroid	disease	in	US	examination.	At	the	time	of	admission	
we	also	assessed	ACTH	level	—	672.9	pg/ml	and	cortisol	—	4.00	μg/	
/dl.	Patient	was	diagnosed	with	both:	hipermetabolic	and	adrenal	
crisis.	Initially	he	was	treated	with	intravenous	thiamazole	(80	mg	
per	day)	and	dexamethasone	(16	mg	per	day)	with	rapid	improve-
ment	of	his	general	condition.	In	the	long	term	treatment	thiamazole	
(20	mg	per	day),	hydrocortisone	(40	mg	per	day),	and	fludrocorti-
sone	(0.1	mg	per	day)	were	used.
Coexistence	of	Addison’s	disease	with	Graves’	disease	is	observed	in	
13%	of	patients	with	adrenal	insufficiency.	The	vast	majority	of	them	
are	women.	The	combination	of	these	diseases	is	part	of	the	type	2	
autoimmune	polyglandular	syndrome.	The	coexistence	of	exacerbation	
of	both	conditions:	adrenal	insufficiency	and	Graves’	disease	is	rare.
P12:  
A difficult diagnosis: a case report of combined Riedel’s 
disease and fibrosing Hashimoto’s thyroiditis
R. Junik1, O. Juraniec1, A. Marszałek2, J. Pypkowski3,  
A. Krymer4
1Department of Endocrinology and Diabetology, Collegium Medicum in Bydgoszcz, 
Poland 
2Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Poland 
3Department of General and Endocrine Surgery, Collegium Medicum in Bydgoszcz, 
Poland 
4Outpatient Clinic of Endocrinology, 10 Military Hospital, Bydgoszcz, Poland
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The	authors	report	a	case	of	a	female	patient	displaying	clinical,	
laboratory	and	 radiological	 traits	of	Riedel’s	 thyroiditis	 and	Ha-
shimoto’s	disease.
Patient Findings: A	44-year-old	Caucasian	female	was	diagno-
sed	with	hypothyroidism.	A	fine-needle	aspiration	biopsy	was	
performed;	findings	were	suggestive	of	an	exacerbated	chronic	
inflammatory	 process,	 however	 a	 small	 lymphocyte-derived	
malignancy	could	not	be	ruled	out	with	certainty;	 the	patient	
was	 referred	 for	 elective	 thyroidectomy.	 The	microscopic	 fe-
atures	of	specimens	did	not	meet	the	criteria	of	Hashiomoto’s	
thyroididtis.	 The	 immunohistochemical	 studies	 revealed	 few	
scattered	B	lymphocytes	(CD20	positive)	and	numerous	scattered	
T	lymphocytes	(CD3	positive).	Finally,	Riedel’s	thyroiditis	with	
an	 intense	 inflammatory	 infiltrate	 composed	 of	 lymphocytes	
was	diagnosed.
Summary: Reaching	a	diagnosis	was	particularly	difficult	in	this	
patient,	since	Riedel’s	thyroiditis,	the	fibrosing	form	of	Hashimo-
to’s	disease	and	malignant	tumors	of	the	thyroid	can	show	similar	
traits	upon	physical	 and	histopathological	 examination.	As	 the	
clinical	data	were	indicative	of	Hashimoto’s	thyroiditis	and	there	
were	partial	histological	criteria	of	two	forms	of	thyroiditis,	namely	
Hashimoto’s	and	Riedel’s,	the	very	rare	diagnosis	of	a	combined	
disease	was	made.	Dense	B	and	T	lymphocytes	and	some	plasma	
cell	 infiltrates,	 as	well	 as	 the	destruction	of	 thyroid	 follicles	by	
fibrosis	extending	into	surrounding	tissues	were	supportive	of	the	
final	diagnosis.
Conclusions: Differentiating	between	 the	histopathological	 and	
clinical	presentation	of	both	of	the	diseases	in	one	patient	is	difficult,	
primarily	due	to	the	partial	overlapping	of	their	histopathological	
traits.	 In	 order	 to	 avoid	 a	diagnostic	 error,	 a	 close	 cooperation	
between	 the	endocrinologist	 and	pathologist	 is	mandatory.	 It	 is	
the	authors’	opinion	that	in	our	patient	the	two	diseases	existed	
separately,	and	their	coexistence	was	most	likely	coincidental.
P13:  
Influence of radioiodine treatment on thyroid  
volume in patients with subclinical  
hyperthyroidism
G. Kamiński, A. Kowalczyk, Z. Podgajny, M. Bilski
Department of Endocrinology and Radioisotope Therapy, Military Institute  
of Medicine, Warsaw
Introduction: Subclinical	hyperthyroidism	(SH)	concerns	about	1%	
of	population.	The	treatment	of	choice	of	SH	is	radioiodine,	when	
its	reason	is	thyroid	autonomy.
Aim: Assessment	of	influence	of	treatment	with	131-I	on	thyroid	
volume	in	patients	with	subclinical	hyperthyroidism.
Material and methods: 44	patients	(37	women	and	7	men)	at	
age	45.9	±	11	with	over	one	year	history	of	autonomous	SH	
were	included	to	the	study.	Among	them:	38	(86.4%)	with	mul-
tinodular	goiter,	three	(6.8%)	with	parenchymal	goiter	and	two	
(4.5%)	with	single	nodule	goiter.	Thyroid	volume	was	assessed	
by	ultrasound	examinations	which	were	performed	twice:	be-
fore	and	5.7	±	4.2	months	after	TSH	normalization	due	to	131-I	
treatment	in	dose	12.1	±	5.7	mCi.	Radioiodine	uptake	after	24	
hours	was	30	±	15%.	The	local	ethical	committee	approval	has	
been	obtained	earlier.
Results: Radioiodine	treatment	patients	with	SH	caused	30%	de-
crease	of	thyroid	volume	(from	33	to	22	ml	—	p	<	0.001).
Conclusion: Treatment	with	radioiodine	of	patients	with	autono-
mous	subclinical	hyperthyroidism	causes	30%	decrease	of	thyroid	
volume	after	half	a	year.
P14:  
Thyroid function and iodine supply in the group  
of healthy pregnant patients from Mazovia  
— preliminary data
M. Krasnodębska-Kiljańska1, B. Niedźwiedzka3,  
A. Kondracka1, Z. Bartoszewicz1, 2, E. Bar-Andziak1,  
T. Bednarczuk1, 2
1Department of Internal Medicine and Endocrinology, Medical University  
of Warsaw 
2Department of Endocrinology, Mossakowski Medical Research Centre, Polish 
Academy of Sciences, Warsaw 
3Department of Pathological Pregnancy, Medical University of Lodz
Key words: pregnancy,	iodine,	thyroid.
Thyroid	dysfunction	in	pregnant	woman	can	negatively	affect	fetal	
development	and	pregnancy	course.	Iodine	deficit	has	important	
influence	on	thyroid	function.	Influence	of	physiological	pregnancy	
on	parameters	of	thyroid	function	makes	interpretation	of	labora-
tory	tests	of	thyroid	function	difficult.
Aim: Prospective	 observation	 of	 thyroid	 function	 and	 iodine	
intake	in	healthy	pregnant	women	supplemented	with	150	μg	of	
iodine	daily.
Methods: Assessment	of	thyroid	function:	concentration	of	TSH,	
free	 thyroid	hormones,	morning	urinary	 iodine	 in	 consecutive	
trimesters	of	pregnancy.
Study group: 40	pregnant	women	(age	24–36	y,	mean	29).	Single	
pregnancies,	resulting	in	birth	of	healthy	neonates.
Results: TSH	concentrations	were	within	values	recommended	for	
pregnancy	and	were:	mean	1.27;	1.92	and	1.73;	median	1.38;	1.92	
and	1.51	IU/l	respectively	in	the	following	trimesters	of	pregnancy.	
Free	T4	was	within	pregnancy	reference	values	and	decreased	in	
the	III	trimester,	mean	concentrations	were	1.26;	1.0;	0.99	ng/dl	in	
subsequent	trimesters.	Urinary	iodine	concentrations	(UIC)	were	
unexpectedly	 low	at	 the	beginning	of	pregnancy:	mean	98	μg/l,	
median	89	μg/l	and	in	62%	of	the	subjects	were	lower	than	100	μg/l.	
In	spite	of	 supplementation	with	at	 least	150	μg	 iodine	per	day,	
mean	UIC	were	respectively	133	μg/l	and	140	μg/l;	median	122	μg/l	
and	129	μg/l	in	the	second	and	third	trimester.
Conclusions: Observations	are	preliminary:	 1.	TSH	and	 free	T4	
values	did	not	exceed	population	reference	values,	dynamics	during	
pregnancy	was	as	expected.	2.	Low	urinary	iodine	concentration	at	
the	beginning	of	pregnancy	and	during	supplementation	reveals	
that	recommended	prophylaxis	does	not	ensure	sufficient	iodine	
supply	in	the	group	of	pregnant	women.
P15:  
The frequency of appearance of autoimmunological 
inflammation of thyroid in patients with protracted 
hepatitis treated with interferon
J. Krupińska1, M. Wawrzynowicz-Syczewska2, A. Syrenicz1
1Endocrinology Clinic, Metabolic and Internal Diseases PUM in Szczecin 
2Department of Infectious Diseases and Hepatology, PUM, Szczecin, Poland
Introduction:	Current	methods	of	 treating	 infectious	hepatitis	
are	linked	to	usage	of	interferon	and	ribavirin.	When	treated	with	
interferon	side	effects	appear	like	thyroid	diseases.
Objectives: The	frequency	of	appearance	of	autoimmunological	
inflammation	of	thyroid	in	patients	with	protracted	hepatitis	treated	
with	interferon.
Methods: The	research	was	participated	by	149	people	with	pro-
tracted	hepatitic	type	B	and	C,	aged	18	to	70:	average	43.9	years	
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±	12.87.	Patients	before	treatment,	after	6	and	12	months	of	treat-
ment	density	of	serum	was	assessed	in:	thyroid	stimulating	hormo-
ne	(TSH),	free	thyroxine	(fT4),	triiodothyronine	(fT3),	thyroglobulin	
(Tg),	antithyroid	antibodies:	thyroid	peroxidase	antibodies	(ATPO)	
and	thyroglobulin	antibodies	(ATG).	Additionally	the	echostructure	
of	thyroid	USG	was	assessed.	Patients	with	thyroid	dysfunctions	
had	the	used	interferon	compliance.	24	patients	were	diagnosed	
with	AZT	when	12	were	treated	with	pegylated	interferon	and	12	
with	recombinant	interferon.	Among	all	149	patients	60	were	given	
pegylated	interferon	and	89	recombinant	interferon.
Results: Research	on	patients	with	protracted	hepatitis	 before	
treatment	with	interferon	found	9	of	them	(6.04%)	with	increased	
density	of	antithyroid	antibodies.	In	this	group	6	were	in	euthyroid	
(during	treatment	4	patients	appeared	to	have	underactive	thyroid,	
1	overactive	thyroid	and	1	with	changing	thyroid	functions	first	
overactive	and	then	underactive)	and	another	3	patients	with	hy-
pothyroidism	(during	treatment	2	patients	maintained	underactive	
thyroid	and	1	appeared	to	have	euthyroid).	24	patients	(17.14%)	on	
interferon	treatment	who	firstly	did	not	show	any	features	of	auto-
immunological	process,	were	diagnosed	with	increased	antithyroid	
antibodies.	The	average	results	for	ATPO	before	and	after	6	and	
12	months	were:	12.4,	310.4,	141.3	IU/ml.	For	ATG:	17.40,	108.0,	
125.6	IU/ml.	In	this	group	of	patients	after	3	months	of	treatment	
3	got	overactive	thyroid,	and	1	underactive	thyroid,	after	6	months	
11	were	diagnosed	with	overactive	thyroid	and	6	with	underactive	
thyroid.	After	12	months:	4	patients	with	overactive	thyroid	and	
1	new	diagnosed,	1	with	change	from	hypothyroidism	to	hyper-
thyroidism,	2	continued	with	overactive	thyroid,	4	with	hypothy-
roidism	and	rest	 in	condition	of	euthyroid.	Whole	group	before	
treatment	on	USG	showed	decreased	echogenicity	of	thyroid	gland	
on	14.7%,	after	6	months	18%	and	after	12	months	22.5%.
Findings: Patients	 treated	with	 interferon	because	of	protracted	
infectious	hepatitis	are	 in	 risk	of	progress	of	new	or	 strength	of	
existing	autoimmunological	inflammation	of	thyroid.	Kinds	of	used	
interferon	do	not	show	relationships	with	thyroid	gland	disorders.
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Introduction: Resistance	 to	 thyroid	hormone	 is	 the	 syndrome	
(RTHS)	with	variable	degree	of	 tissue	hyposensitivity	to	thyroid	
hormones.	Patients	with	RTHS	have	elevated	FT4	and	FT3	with	non	
suppressed	TSH.	Traditionally	syndrome	is	classified	as	generalized,	
pituitary	or	peripheral	type.
The aim was	presentation	of	 the	RTHS	clinical	picture	and	 the	
impact	of	concomitant	thyroid	diseases	on	its	course	in	our	material.
Material: 3	 females	 and	one	male	 aged	 47–62,	 hospitalized	 in	
2006–2011.
Methods. Clinical	picture	and	diagnostic	procedures	needed	for	
confirmation	of	thyroid	disorders	have	been	performed.
Results: Female 58, with	 cardiologic	 disorders,	 suspected	 of	
amiodarone-induced	thyrotoxicosis.	 In	 the	past,	she	was	treated	
many	 times	with	antithyroid	drugs	because	of	 elevated	 thyroid	
hormones.	 Small	 goiter.	 FT4	 38.5	pmol/L,	 FT3	 8.6	pmol/l,	 TSH	
4.63	IU/l.	TSH	after	TRH	=	19.27	IU/l.	MRI	excluded	pituitary	ade-
noma.	Clinically	euthyroid.	Male 62, with	bilateral	forearm	fracture.	
Normal	thyroid	size.	Before	surgery,	in	routine	thyroid	hormone	
evaluation:	FT4	24.4	pmol/l,	FT3	7.4	pmol/l,	TSH	2.14	IU/l.	TSH	after	
TRH	=	7.65	IU/l.	Clinically	euthyroid.	Female 59, in	the	past	sub-
total	thyreoidectomy	because	of	toxic	nodular	goiter.	Hospitalized	
with	the	symptoms	of	severe	hypothyroidism	after	thyreostatics	
due	 to	 recurrent	 hyperthyroidism,	with	 concomitant	 normal	
FT4	and	FT3	concentrations	and	TSH	>	77.9	IU/l.	After	cessation	
of	the	antithyroid	therapy,	hyperthyroidism	recurred	with	FT4	
—	29.1	pmol/l,	FT3	—	5.8	pmol/l.	TSH	24.9	IU/l.	TSH	after	TRH	=	
=	58.13	 IU/l.	MR	 imaging	revealed	normal	pituitary.	Female 47, 
with	 the	 symptoms	of	hyperthyroidism.	After	pharmacological	
treatment	clinically	euthyroid	with	FT4.44	pmol/l,	FT3	5.8	pmol/l,	
TSH	1.8	IU/l.	TSH	after	TRH	=	9.5	IU/l.	High	levels	of	TSI	and	TPO	
autoantibody,	 confirmed	concomitant	 autoimmunologic	 thyroid	
disease.	Normal	pituitary	MR	imaging.
Conclusions: RTHS	 is	 characterized	by	 large	heterogeneity	 of	
clinical	picture.	Coexisting	thyroid	disorders	complicate	its	course	
and	can	cause	diagnostic	difficulties.
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Introduction: Thyroid	disorders	including	Hashimoto’s	thyroidi-
tis	tend	to	be	observed	more	frequently	in	women	with	Turner’s	
syndrome.	Hypothyroidism	is	reported	in	16–87.5%	of	those	pa-
tients	and	hyperthyroidism	only	in	2.5%.	In	women	with	Turner’s	
syndrome,	as	well	as	in	the	general	population,	the	frequency	of	
thyroid	abnormalities	increases	with	age.	There	is	no	difference	in	
the	incidence	of	thyroid	dysfunction	related	to	the	form	of	kary-
otype	abnormality.
The	aim of study was	 to	 evaluate	 the	 frequency,	 etiology	 and	
forms	of	thyroid	pathology	in	group	of	adult	women	with	Turner’s	
syndrome	treated	in	our	clinic.
The	study group included	11	 females	 aged	23	 to	 72	years.	The	
diagnosis	of	Turner’s	syndrome	was	based	on	the	clinical	picture	
and	a	karyotype	test.
Methods: The	patients	were	screened	for	thyroid	abnormalities	by	
clinical	evaluation	and	laboratory	examination.	The	laboratory	as-
sessment	included	thyroid	structure	(USG),	thyroid	function	(TSH,	
FT4,	FT3)	and	antithyroid	antibodies.	The	 tests	were	performed	
using	standard	hospital	laboratory	procedures.
Results: Thyroid	pathology	was	detected	in	9	cases	(82%).	Chronic	
lymphocytic	 thyroiditis	was	diagnosed	 in	 seven	 female	patients	
with	hypothyroidism	(63.7%)	and	Graves’	disease	was	found	in	one	
patient	with	hyperthyroidism.	Normal	thyroid	function	was	confir-
med	in	one	patient	with	an	elevated	level	of	anti-TPO	antibodies	and	
in	another	one	with	nodular	goitre	in	an	ultrasound	examination.
Conclusion: 1.Thyroid	pathology	 is	 the	most	 frequent	 form	of	
endocrinological	disorders	 in	patients	with	Turner’s	 syndrome.	
2.	Hashimoto’s	thyroiditis	and	hypothyroidism	are	the	most	preva-
lent	types	of	thyroid	disorders	in	women	with	Turner’s	syndrome.
